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Abbreviations 
' .......................  minutes 
'' ......................  seconds 
µg ...................  micrograms 
µm ..................  micrometers 
AB ..................  antibiotic 
Amp ................  Ampicillin 
APC ................  antigen presenting cell 
BG(s) ..............  Bacterial Ghost(s) 
bp ....................  basepairs 
BPL ................  beta-propiolactone 
cfu ...................  colony forming unit 
dH2O ...............  deionized water 
E.coli ..............  escherichia coli 
E-protein .........  Lysis Protein E from ΦX174  
(Blasi, Young et al. 1988; Witte, Blasi et al. 1990) 
Gent ................  Gentamycin 
h ......................  hours 
IS ....................  immunse system 
Kan .................  Kanamycin 
kb ....................  kilobasepairs 
kDa .................  kilo Dalton 
l .......................  liter 
LacI-L'anchor .  L’ anchor membrane anchored LacI  
repressor (Mayrhofer, Tabrizi et  
al. 2005) 
LBv ................  vegetable LB medium 
(animal product free) 
LPS ................  lipopolysaccharide 
M ....................  marker 
mg ..................  milligrams 
MHC ..............  major histocompatibility complex 
min .................  minutes 
miniprep .........  plasmid preparation 
nm ..................  nanometer 
ODxxx ..............  optical density at indicated wavelength 
ori ...................  origin of replication 
PamP ..............  pathogen associated molecular pattern 
parA ...............  partitioning Resolvase  
(Kreiss, Cameron et al. 1998) 
PBAD ................  arabinose inducible Promoter  
(Bigger, Tolmachov et al. 2001) 
PBS ................  phosphate buffered saline 
PCR ................  polymerase chainreaction 
s ......................  seconds 
Strep ...............  Streptomycin 
Tet ..................  Tetracycline 
tp ....................  timepoint 
WB .................  Western blot 
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Summary 
Objective 
Goal of this work was the production of Bacterial Ghosts (BGs) loaded with pSIP-H5 minicircle, a 
small DNA molecule harboring a Eukaryotic Expression Cassette for the protein Hemagglutinin type 5 
of the H5N1 avian influenza virus. This composes a DNA vaccine for poultry enclosed in BGs, which 
act as biological carrier vehicles, directly targeting the cellular as well as activating the adaptive 
immune system. 
In combination with the Bacterial Ghost (BG) technology, the SIP (self-immobilizing-plasmid)-
technique provides an easy, cheap and safe way of mass production of the vaccine.  
The characteristic of the SIP-technique is the division of the original (SIP-) motherplasmid into two 
sub-parts, the minicircle, including, next to the H5 Expression Cassette, the ability to fix itself within 
the bacterial membrane and the miniplasmid, containing the undesirable sequences, which is lost with 
the cytoplasm upon E-lysis of the bacterial cells. 
The aim was the design of a SIP plasmid containing the H5 gene, the pSIP-H5, which recombines 
upon arabinose induction, losing all sequences necessary for fermentation and possibly harmful when 
introduced into a target organism, like the antibiotic resistance cassette or the origin of replication.  
pSIP-H5 would then be co-transformed with pGLysivb into E.coli, which induces E-lysis of the 
bacterial cell upon temperature shift. In one fermentation procedure recombination of the pSIP-H5 is 
induced, after that E-lysis is performed, H5-minicircle loaded BGs are obtained. 
Next to cloning this plasmid the objective is to decide on the plasmid-carrying bacterial strain. The 
important properties of the strain are efficient lysis upon temperature shift and prompt and complete 
recombination as well as tight suppression of untimely recombination. Another beneficial property is 
the tropism of the bacterial strain to the vaccine recipient, such as salmonella, as a natural pathogen of 
poultry. 
Results 
In the presented diploma thesis the Influenza Gene H5 was cloned into the Self Immobilizing SIP 
Vector and the amount of bound DNA-minicircle in E.coli BGs was measured. pSIP-H5 minicircle-
DNA binds with help of its Lac-Operator region to the membrane-anchored Lac-Repressor and thus is 
retained within the cell envelope and not expelled into the medium after E-Lysis of the bacteria. 
The results of the sequencing of the amplified H5 Sequence of the plasmid pEPH5 showed 62 
additional basepairs, which are located in the non-coding region of the fragment. No influence of that 
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sequence on recombination or fixation of the minicircle, carrying the into the SIP vector cloned H5 
gene, was observed. 
Transformation of different E.coli strains with pSIP-H5 showed problems with premature 
recombination. Within the E.coli strains DH10β, ER2655 and TOP10 uninduced recombination of 
pSIP-H5 into miniplasmid and minicircle was confirmed. 
In the E.coli strain TB1 without induction of expression of the parA recombinase no premature 
recombination was observed, however, recombination upon induction was poor and inefficient. These 
are the reasons why the E.coli strain TB1 was used for amplification of pSIP-H5. Within the 
Salmonella strain ATCC14028, which was also used for parA recombination experiments, premature 
recombination was shown as well. Based on these data the E.coli strains DH10β, ER2655, TOP10 and 
TB1 as well as the Salmonella strain ATCC14028 were abandoned from further investigations. 
Recombination of pSIP-H5 and Lysis of bacteria, the production of BGs was carried out with the 
E.coli strain NM522. Successful recombination and expression of the LacI-L’anchor was documented 
by plasmid preparation and Western Blot. 
The H5-minicircle was detected by realtime PCR, which was applied on washed and lyophilized BG 
samples, amplifying the LacOs sequence, located on the minicircle. 
With this technique up to 12 thousand H5-minicircles per BG (saline washed) and more than 2000 H5-
minicircles per BG (washed with dH2O) were detected. 
Plasmid preparation of washed, lyophilized BGs showed a minicircle- as well as a miniplasmid band. 
Despite additional and adapted washing with saline later plasmid preparation still showed minicircle 
and miniplasmid band. 
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Zusammenfassung 
Zielsetzung 
Ziel dieser Arbeit war die Produktion von Bacterial Ghosts (BGs) beladen mit pSIP-H5 minicircle, ein 
kleines DNA Molekül, das eine eukaryotische Expressionkassette des Haemagglutinin Proteins Typ 5 
des aviären H5N1 Influenza Virus trägt. Diese Komposition resultiert in einem DNA Impfstoff für 
Geflügel eingeschlossen in BGs, die als natürliches Trägermedium fungieren, direkt vom zellulären 
Immunsystem erkannt werden und das adaptive Immunsystem aktivieren. 
In Kombination mit der Bacterial Ghost (BG) Technologie ist das SIP-system eine einfache, günstige 
und sichere Methode diesen Impfstoff in großen Mengen herzustellen. 
Die essentielle Eigenschaft des SIP-Systems ist die Teilung des originären (SIP-) ‚Mutterplasmides‘ in 
zwei Untereinheiten, den Minicircle, der die H5 Expressionskassette enthält und die Fähigkeit sich an 
der Zellmembran zu fixieren hat, und das Miniplasmid, das alle unerwünschten Sequenzen trägt und 
bei der Lyse der bakteriellen Zellen mit dem Cytoplasma ausgeschwemmt wird. 
Das Ziel war das Klonieren eines SIP-Vektors, pSIP-H5, der das H5 Gen enthält. Dieses Plasmid 
rekombiniert durch Arabinose-Induktion und verliert dadurch alle für die Fermentation notwendigen 
und für einen Endorganismus potentiell gefährlichen Sequenzen, wie antibiotische Resistenzkassetten 
oder den Origin of Replication. 
pSIP-H5 sollte mit dem Lyseplasmid pGLysivb in verschiedene E.coli Stämme co-transformiert 
werden, das nach Temperaturshift die E-Lyse der Bakterienzelle induziert. In einem 
Fermentationsschritt rekombiniert das pSIP-H5, danach wird die E-Lyse induziert; man erhält mit H5-
Minicircle beladene BGs. 
Die zweite Aufgabe der Arbeit ist es, einen geeigneten Bakterienstamm für das pSIP-H5 zu finden. 
Die wichtigen Eigenschaften des Stammes sind effiziente Lyse nach Temperaturshift und schnelle 
vollständige Rekombination des pSIP-H5 nach Arabinose Induktion sowie strikte Unterdrückung von 
vorzeitiger Rekombination. Eine weitere günstige Eigenschaft des Stammes besteht in einem BG-Wirt 
Tropismus, wie es bei Salmonellen als natürliches Pathogen von Geflügel der Fall ist. 
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Resultate 
In der vorliegenden Diplomarbeit wurde das Influenza Gen H5 in den Selbst-Immobilisierungs-Vektor 
SIP kloniert und die Menge der gebundenen Minicircle-DNA in E.coli BGs bestimmt. pSIP-H5 
Minicircle-DNA bindet mit Hilfe seiner Lac-Operator Region an den Membran-verankerten Lac 
Repressor und wird dadurch in bei der E-Lyse der Bakterien nicht in das Medium ausgeschieden 
sondern im Zellenvelope gebunden. 
Die Ergebnisse der Sequenzierung des amplifizierten H5 Stücks des Plasmids pEPH5 zeigten 62 
zusätzliche Basenpaare, die im nicht-kodierenden Bereich des Fragments liegen. Ein Einfluss auf die 
Rekombination oder die Fixierung des Minicircles, welcher den in den SIP Vektor klonierten H5 Gens 
enthält, durch diese Sequenz wurde auf jeden Fall nicht festgestellt. 
Die Transformation verschiedener E.coli Stämme mit pSIP-H5 zeigte Probleme mit frühzeitiger 
Rekombination auf. In den E.coli Stämmen DH10β, ER2655 und TOP10 zeigte sich uninduzierte 
Rekombination von pSIP-H5 in die Miniplasmid- und Minicircleform. Im E.coli Stamm TB1 zeigte 
sich ohne Induktion der Expression der parA Rekombinase keine vorzeitige Rekombination, allerdings 
war die Rekombination nach Induktion nicht effizient. Aus diesen Gründen wurde der E.coli Stamm 
TB1 für die Amplifikation von pSIP-H5 verwendet. Im Salmonella Stamm ATCC14028, der für die 
parA Rekombinationsversuche herangezogen wurde, zeigte sich ebenfalls vorzeitige Rekombination. 
Aus diesem Grund wurden die E.coli Stämme DH10β, ER2655, TOP10 und TB1 wie auch der 
Salmonella Stamm ATCC14028 von weiteren Untersuchungen ausgeschlossen. 
Rekombination von pSIP-H5 und Lyse der Bakterien, die Produktion der BGs wurde mit dem E.coli 
Stamm NM522 durchgeführt. Die erfolgreiche Rekombination und die Expression des LacI-L’Anker 
Fusionsproteins wurde mit Plasmid Präparation und Western Blot überprüft. 
Der H5-Minicircle wurde mit Realtime-PCR, die die LacOs Sequenz amplifizieren, welche auf dem 
Minicircle liegt, in Proben von gewaschenen und gefriergetrockneten BGs nachgewiesen. 
Durch die Realtime-PCR wurden bis zu 12 Tausend H5-minicircles pro BG (mit Saline gewaschen) 
und mehr als 2000 H5-Minicircles pro BG (mit dH2O gewaschen) nachgewiesen. 
Plasmid Präparation von gewaschenen, gefriergetrockneten BGs zeigte Minicircle- wie auch 
Miniplasmid Banden. Trotz zusätzlichem und adaptiertem Waschen mit Saline zeigte sich in der 
Plasmid Präparation eine Minicircle- und eine Miniplasmid-Bande in den BGs. 
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Introduction 
Avian Influenza type H5N1 
Since 2003 when the avian influenza type A/H5N1 circulating in Southeast-Asia since 1996, became 
enzootic, the risk of a genetic reassortment of the highly pathogenic and contagious strain poses a 
threat for public health. Reported cases of felines, cats and even dogs further illustrates the unusual 
cross species transmission potential of the virus (Thiry, Zicola et al. 2007). It has been estimated that 
hundreds of millions of birds have been culled so far in an attempt to control the spreading disease. An 
influenza outbreak in the Netherlands in 2003 caused the culling of 30 million birds (Stegeman, 
Bouma et al. 2004), mounting to about half of the nations stock and pushing the EU to permitting the 
vaccination of poultry in this country. Vaccinating poultry not only protects birds from avian 
influenza, but also is an important step to control and minimize the public health risk posed by genetic 
reassortment of the virus. 
The goal of this thesis was to create a DNA vaccine against Avian Influenza Type H5N1 by inducing 
immunity against the Vietnam H5-gene. The H5 gene was incorporated in a eukaryotic expression 
cassette, which was embedded in the plasmid pSIP-H5. 
A large part of the immune response against influenza is directed against the protein HA, which is also 
responsible for the tissue-direction and severity of the infection (Kobasa, Takada et al. 2004; Tumpey, 
Garcia-Sastre et al. 2004). Another DNA vaccine using the Vietnam H5 antigen showed protective 
immunity against lethal H5N1 challenge in mice, 2007 (Sharpe, Lynch et al. 2007). 
Bacterial Ghosts as carriers of a minicircle DNA vaccine 
candidate for avian influenza 
Avian Influenza type H5N1 continues to be a threat for European poultry economy, sustaining the 
need for a vaccine. Several requirements are demanded of a possible vaccine candidate, like 
economical usefulness, high immunogenicity or the fulfillment of food-control standards. Important 
properties are low price, easy mass-production and -administration as well as efficiency and safety. In 
contrast to conventional vaccines, DNA vaccines can be precisely tailored, cheap and easily produced 
by fermentation of the bacteria carrying the DNA and pose no risk of reconversion.  
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The specialty of the SIP-technique (self-immobilizing-plasmid) adds to the safety demand by avoiding 
any possibly harmful DNA sequences. Antibiotic resistance cassettes or origins of replication, which 
are necessary for transformation and fermentation of a plasmid, might propagate antibiotic resistance 
or facilitate horizontal gene transfer and therefore pose a potential risk in DNA vaccines; these 
sequences are lost during the SIP process. 
This way of vaccine production combined with the Bacterial Ghost platform technology results in non 
living carrier vehicles loaded with the vaccine. The BG-DNA complex shows high structural stability 
even at room temperature as well as efficient immunologic availability after administration. 
DNA vaccination 
The first Steps in DNA Vaccine Development 
The research on DNA based vaccines started its boom in the early 1990s with the report on gene 
expression in mouse muscle cells after naked DNA injection (Wolff, Malone et al. 1990). Little were 
these findings anticipated, since the use of naked DNA for injection was intended to be a control for 
experiments designed to assess the ability of cationic lipids to mediate expression in vivo. This 
discovery opened a whole new field of approaches to immunization, immunotherapy and vaccine 
design and production. DNA vaccines are widely investigated to address pathogen and autoimmune 
derived diseases as well as contribute to cancer and allergy treatment. Advanced methods and 
discoveries in immunology, microbiology and molecular biology facilitate engineering of specifically 
tailored gene vaccines in order to direct immune response (humoral, cell-based or both). In this way 
the immunogenicity can either be precisely limited to a desired protein or also target a larger variety of 
antigens; immunogenic molecular factors and pathways can be activated or influenced very 
selectively. 
The Difference of DNA Vaccines to Conventional Vaccines 
Conventional vaccines, which consist of inactivated pathogens or subunits thereof, primarily elicit 
humoral immune response. A certain antibody titer induced by immunization can be very important 
for the efficacy of later immunogenic response to that antigen. Antibodies are responsible for 
inactivation and opsonization of pathogens circulating in the blood, in the intestines as well as in other 
tissues like the mucosa or the cornea. This is done in order to either actually block and inactivate the 
pathogen directly or to draw the attention of the complement system or of cells of the immune system 
to take counter-measures. However, many infectious bacteria and any kind of virus propagate within 
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cells and are thus shielded from antibody attack. Proteins expressed by the cell are randomly cut to 
small peptides of about 10-20 amino acids by proteases and displayed at the cell surface connected to 
the MHC-complex (fig 1.1). This complex is recognized by the cytolytic T-cell, which eventually will 
induce apoptosis of the displaying cell and recruit other immune cells, if the peptide shown in the 
complex is foreign or abnormal as in cancer cells. This is a very important part of the immune system 
covering threats from internalized pathogens or cancer, killing infected or cancerous cells and with 
that hinder pathogen or tumor proliferation. The integral mechanism of DNA vaccines is the 
intracellular transcription and translation of introduced genetic information within the host cell and is 
therefore especially suitable to establish T-cell based immune response (Fu, Guan et al. 1998; Ulmer, 
Fu et al. 1998).  
 
 
 
 
 
 
 
 
 
Plasmid DNA vaccines induce immunogenicity in several different ways (fig 1.2). Innate immunity is 
activated through non methylated CpG motifs via the TLR9, which leads to activation of the adaptive 
immune system via inflammatory and immune response genes and is discussed below in detail 
(Klinman, Yamshchikov et al. 1997; Krieg, Yi et al. 1998; McCluskie, Weeratna et al. 2000; Bauer, 
Kirschning et al. 2001; Kovarik, Bozzotti et al. 2001). After DNA uptake the encoded antigen is 
Fig 1.1: Antigen Presentation by MHC-I. After infection, expressed viral proteins are cleaved into oligopeptides by proteasomes and 
taken up by the ER, where MHC-I molecules are newly synthesized. The antigen peptide is taken up by the MHC-I molecule and via 
the Golgi-apparatus transported to the cell membrane and presented to the outside. This MHC-I bound antigen complex is recognized 
by the corresponding T-cell receptor in combination with the CD8 molecule present on CD8+ cytotoxic T-cells. The combined binding 
of the T-cell receptor and the CD8 molecule results in activation of the T-cell. In immediate consequence NFκB, INF-γ and Interleukins 
are expressed, followed by Granulocyte/Macrophage-Colony Stimulating Factor. (Ulmer, Wahren et al. 2006) 
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produced in situ by host-cells, which leads to the same modifications, folding and posttranslational 
processing of the antigen compared to the normal infection, so, very likely the antigen shows similar 
properties (Babiuk, Babiuk et al. 2000) for eliciting a corresponding immune response. Although it is 
not fully understood how DNA-uptake, transfer to nucleus and transcription mechanism come about, it 
has abundantly been shown, that DNA expression upon DNA introduction occurs plentifully (Wolff, 
Malone et al. 1990; Ulmer, Donnelly et al. 1993; Montgomery, Donnelly et al. 1994; Davis 1997; 
Ulmer, Deck et al. 1997). B-cell response has been shown by different groups (Kovarik, Bozzotti et al. 
2001; Hobson, Barnfield et al. 2003; Rush, Mitchell et al. 2006) indicating means to initiate an 
antibody response after DNA vaccination. The main immune stimulatory mechanism however, is 
believed to be encoded gene expression followed by ubiquitination, further degradation by 
proteasomes and subsequent antigen peptide presentation in complex with the MHC complex, which is 
displayed on the outer membrane of cells (Ulmer, Deck et al. 1997; Fu, Guan et al. 1998; Uchijima, 
Yoshida et al. 1998). T-cell activation is restricted to antigen presenting cells, like dendritic cells or 
macrophages, which express the MHC-II complex. Thus, in order to activate (‘prime’) naïve T-cells 
either the APCs have to be transfected with the plasmid vaccine themselves or they take up the peptide 
by cross-priming (fig 1.3) (Fu, Guan et al. 1998; Donnelly, Liu et al. 2000; Heit, Maurer et al. 2003; 
Srivastava and Liu 2003). T-cell priming by DCs or other professional antigen presenting cells is 
widely considered to be the important factor of inducing cellular based immune response (Cusi, 
Terrosi et al. 2004). Since naked DNA uptake takes place primarily in MHC-II
-
, MHC-I
+
 cells, which 
is the predominant majority of cells in the body  (e.g. myocytes, when vaccination route is injection 
into the muscle) many different groups work on vaccine delivery techniques targeting especially DCs 
(Denis-Mize, Dupuis et al. 2000; Donnelly, Liu et al. 2000; Kutzler and Weiner 2004; Lu, Kawakami 
et al. 2007). 
 
        
 
 
 
 
 
 
Fig 1.2: Inducing Immunogenicity in 
many different ways. DNA vaccine 
activation of the immune system. After 
DNA-uptake by the cell (1), several 
different ways are postulated to start 
immune-reaction. In case of transfected 
MHC-II+ cells direct priming occurs (2). 
Cross priming may play some role in 
antigen presentation and ‘secondary’ 
priming of T-cells (3). Innate immune 
system is triggered by unmethylated CpG 
motifs, recognized by TLR9 (4). 
adapted from (Srivastava and Liu 2003) 
17 
 
 
Drawbacks and Approaches to Problems of limited Bioavailability of introduced genes 
and gene products respectively 
However, despite the new range of possibilities and promising results in small model organisms, DNA 
vaccines do not provide sufficient immune response in clinical trials so far (Cohen, Boyer et al. 1998; 
Boyer, Kim et al. 1999; Roy, Wu et al. 2000; Swain, Heydenburg Fuller et al. 2000; Wahren, 
Ljungberg et al. 2002; Hejdeman, Bostrom et al. 2004; Levine, Humeau et al. 2006). The main reason 
for the differences in immunogenic outcome has not yet been elucidated in detail, but is believed to be 
found in limited bioavailability of the immunizing agent (Ulmer, Wahren et al. 2006). Starting with 
low transfection rates, low expression levels, restriction of the antigen encoding plasmid DNA to 
injection site and, as a consequence of these shortcomings, insufficient stimulation of the innate 
immune system, which is responsible for a thorough activation of the adaptive immune system 
(reviewed by (Ulmer, Wahren et al. 2006)).  
 
Several approaches try to overcome those problems on various levels of the immunization procedure 
Vector alterations 
In general vectors for gene based immunization consist of 5 essential sites, divided into two subsets. 
First there is the bacterial origin and a selective marker (e.g. an antibiotic resistance cassette) 
responsible for plasmid propagation and selection in the bacteria, which is the main production site for 
plasmid DNA. Second, there is the eukaryotic expression cassette, containing a eukaryotic promoter 
sequence, the encoded (anti-)gene as well as a polyA tail. (Xu, Mizuguchi et al. 2001) tested several 
different promoters and polyA sequences concerning their strength of gene expression within the 
vectors. Among others tested, the CMV IE promoter (cytomegalo-virus immediate early), the β-actin 
promoter of chicken with the β-actin intron sequence and the improved CMV-promoter containing the 
largest CMV intron sequence (intron A) produced the highest levels of expression. The polyA 
Fig 1.3: Crosspriming. Priming T-cells. T-
cell priming is restricted to APCs 
(Macrophages and, more important, 
Dendritic cells) and two ways of achieving 
antigen information are proposed: Either 
direct transfection of the APC, expression 
and presentation of the antigen, which is 
supposed to play the major role of T-cell 
priming, or antigen acquisition through 
cross-priming by myocytes. 
adapted from (Srivastava and Liu 2003) 
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sequences with the most stable gene expression found, were the SV40 (simian vacuolating virus 40) 
and the BGH (bovine growth hormone) polyAs (Xu, Mizuguchi et al. 2001). 
Also codon optimization proved to be a powerful tool to increase gene expression. (Wang, Farfan-
Arribas et al. 2006) showed that codon optimization enhanced the efficiency of gene expression. 
Surprisingly codon optimization also showed increased levels of mRNA suggesting that tRNA 
availability is not the only reason for improved gene expression (Uchijima, Yoshida et al. 1998; 
Nagata, Uchijima et al. 1999; Deml, Bojak et al. 2001; Narum, Kumar et al. 2001; Bojak, Wild et al. 
2002; Wang, Farfan-Arribas et al. 2006).  
Adjuvant addition  
Another given reason for poor immunogenicity of DNA vaccines is the insufficient stimulation of the 
innate immune system. This stimulation is crucial for providing thorough immune response to any 
kind of vaccine. The adjuvant helps by mocking actual disease and with that, induce inflammatory 
response genes. Conventional vaccines, which mostly also need an adjuvant boost, are often co- 
administered with aluminum salts or other substances known to stimulate the innate immune response. 
Plasmid DNA itself has a built-in adjuvant with unmethylated CpG motifs, which are recognized by 
TLR9 (toll-like-receptor), which is present in lymphocytes, NK-cells and on the membrane of DC 
endosomes (fig 1.2) (Klinman, Yamshchikov et al. 1997; Bauer, Kirschning et al. 2001). Activation of 
TLR9 results in proliferation of the cell and/or secretion of immune modulatory cytokines (IL-1, IL-6, 
IL-12, IL-18, TNFα and INFγ), chemokines and polyreactive IgM (Kovarik, Bozzotti et al. 2001). In 
addition CpG motifs enhance the expression of MHC II co-stimulatory molecules like B7-2, CD40 
and ICAM-1. Thus, lots of research elucidated power and modality of the immune activating 
properties of CpG motifs (Wagner and Bauer 2006). A recent finding of the use of control DNA (i.e. 
without an encoded gene) showed increased levels of INF-regulated genes in mice indicating the 
possibility of a TLR9 independent immunological mechanism affected by DNA (Cohen, Boyer et al. 
1998). Another possibility to enhance innate immune system response is the additional cloning of 
genes of interleukins, chemoleukins and co-stimulatory molecules into the vaccine plasmid and in this 
way boosting inflammatory pathways (Kutzler, Robinson et al. 2005; Leitner, Bergmann-Leitner et al. 
2006). It also has been tried to simply add these immune stimulants to the vaccine as adjuvant 
(Kutzler, Robinson et al. 2005). The composition of adjuvants also enables manipulation of immune 
response and directs the outcome either to cell based or humoral immunogenicity. As pars pro toto the 
findings of the use of IL-15 expression are mentioned. IL-15 is a very important cytokine to sustain 
proliferation of CD8
+ 
memory T-cells. IL-15 use did not show high effect due to low expression levels 
in situ. However, (Kutzler, Robinson et al. 2005) showed increased efficacy in mice for HIV and 
influenza DNA vaccines with an optimized IL-15 expression plasmid. The study showed enhanced 
CD8
+
 T-cell proliferation, longevity and effector function, which lead to increased immunogenicity 
and protective efficacy (Zhou, Zhang et al. 2006). This way of manipulation is very helpful if 
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distinguished CD8
+
 T-cells are wanted as answer to intracellular pathogens. On the other hand 
different adjuvant composition may also elicit CD4
+
 T-cell based immune response as answer to an 
allergic disease. 
Addition of non-directly-immunogenic sequences  
(Zhou, Zhang et al. 2006) showed the possibility of increasing immunologic response by down-
regulation protein expression of SOCS (suppressor of cytokine signaling) family genes in 
lymphocytes. This was achieved by co-administration of siRNA transcription vector with a CML-28 
TAA (tumor associated antigen) expression vector. Immunogenic response and lymphocyte 
proliferation was significantly higher in SOCS silenced lymphocytes compared to cells immunized 
only with the CML-28 TAA (Kim, Hung et al. 2004; Zheng, Babiuk et al. 2005). 
Immunologic availability 
The limited number of transfected cells is thought to be a reason for poor immune reaction. Efforts 
have been made to fuse antigen-proteins with the VP22 protein of HHV type1 (Perkins, Hartley et al. 
2005). This enables the spreading of the fusion protein from cell to cell to increase the number of 
responding cells to vaccination. Although various groups could show an increased immune response in 
mice and cattle, still the theory behind the rise is controversial (Ulmer, Donnelly et al. 1993; Bennett, 
Phillpotts et al. 1999; Dubensky, Liu et al. 2000; Singh, Briones et al. 2000; Briones, Singh et al. 
2001; O'Hagan, Singh et al. 2002; Otten, Schaefer et al. 2005). It is thought that VP22-fusion proteins 
result in intercellular spreading.  
Variation of delivery methods  
Many different ways of applying foreign DNA to cells have been tried, reaching from naked DNA 
injection, in vivo electroporation and ‘tattooing’ (a method similar to former Variolation) over particle 
based delivery using the tendency of APCs (such as macrophages and dendritic cells) to phagocytose 
particles in the range of µm, to vector (viral and bacterial) associated DNA-delivery and gene gun 
application (Sasaki, Takeshita et al. 2003). It was shown in numerable publications that different 
delivery methods of DNA vaccines on the one hand show different efficiency of transfection, antigen 
expression and bioavailability of the antigen, and on the other hand influence the outcome of 
immunogenic response base, i.e. again a means to direct immune response either to cellular or humoral 
activation. It has been shown, that delivery systems which introduce the vaccine to the extracellular 
lumen (i.e. by injection) elicit humoral inclined immune response, whereas plasmid DNA directly 
introduced into the cytoplasm (i.e. via gene gun or electroporation) rather activates cell-based 
immunity. (Bagarazzi, Boyer et al. 1999; McCluskie and Davis 1999; Hobson, Barnfield et al. 2003) 
proposed that the reason for the difference is due to the recognition of the CpG elements by TLR9 
when the plasmid is located outside the cell. This discrepancy however, remains conjectural. 
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Until now (2008) there are four DNA based vaccines licensed, which are for the use in animals. One is 
APEX-IHN® against the infectious hematopoietic necrosis Virus in rainbow trout (August 2005, 
CFIA), the second is West-Nile Innovator® against West-Nile Virus in horses (July 2005, CDC). Both 
vaccines are delivered intramuscularly. 
Two more have been licensed more recently. In 2007, a therapeutical DNA vaccine against melanoma 
in dogs has conditionally been licensed in the US, called Canine Melanoma Vaccine. Companies 
involved are Merial, Memorial Sloan–Kettering Cancer Center and The Animal Medical Center of 
New York.  
The last licensed DNA vaccine increases the number of piglets weaned in breeding sows; significantly 
decreases perinatal mortality and morbidity. It is called LifeTide-SW5, and used in swine. Licensed in 
Australia in 2007 from VGX Animal Health. 
Alternative delivery: Mucosal Application 
Besides those invasive, parenteral ways of introducing DNA into the body, application of suitable 
delivery systems onto the mucosa poses another way of immunization and the possibility to specially 
induce mucosal IgA-antibodies as well as a systemic response (Babiuk, Pontarollo et al. 2003). 
Additionally the density of DCs is very high in the mucosa, which increases the possibility of uptake. 
Protective mucosal immunity is crucial for inactivation of many pathogens at the entry site, thus 
preventing infection at the very first stage, on the other side mucosal immunization is a desirable way 
of applying large-scale vaccination. Its administration is easy and fast, needles as well as highly 
trained personnel are not needed. It was also shown, that mucosal vaccination (e.g. nasal) induces 
immunity in other mucosal tissues as well (e.g. vaginal) (Haslberger, Kohl et al. 2000).  
Bacterial Ghosts (BGs) provide a very effective carrier vehicle for mucosally delivered DNA vaccine. 
Due to natural membrane proteins and further so-called Pathogen associated Molecular Patterns 
(PaMPs) directly targeting DCs and macrophages (Witte, Blasi et al. 1990), in this way adding to the 
efficient transfection of immune competent cells as well as providing intrinsic adjuvant properties like 
peptidoglycan, lipopolasaccharides and lipid A. 
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Bacterial Ghosts 
The Process of Producing Bacterial Ghosts: E-Lysis 
BGs are non-living, gram-negative bacterial envelopes devoid of cytoplasm but with an intact shell 
(fig 1.4, 1.5). This is achieved by the in vivo generation of a lysis hole through the inner and outer 
membrane by the phage-derived lysis-protein E from phage PhiX174 (Blasi, Young et al. 1988). This 
protein forms a lysis tunnel by fusing the inner and outer membranes, leaving the integrity of the 
envelope structure otherwise unharmed and expelling the cytoplasm by osmotic pressure difference 
with the surrounding medium (Szostak, Hensel et al. 1996). The so produced BGs are then subjected 
to lyophilisation, which renders them stable at room temperature (Eko, Hensel et al. 1994; Eko, 
Szostak et al. 1994; Szostak, Hensel et al. 1996; Szostak, Mader et al. 1997; Eko, Witte et al. 1999; 
Jalava, Hensel et al. 2002; Marchart, Dropmann et al. 2003; Panthel, Jechlinger et al. 2003; Ebensen, 
Paukner et al. 2004; Eko, He et al. 2004; Mayr, Haller et al. 2005; Mayr, Walcher et al. 2005; 
DelVecchio, Alefantis et al. 2006; Eko, Barisani-Asenbauer et al. 2007). 
 
 
 
 
 
Findings suggest the building of the lysis hole near the cell division zone. 
BGs are manufactured by transforming Escherichia coli cells with the lysis plasmid pGLysivb. This 
plasmid harbors the E-lysis gene under the control of the temperature dependent λ-Promoter, which is 
active at 42°C and silent at 36°C. Increasing the temperature from 36°C to 42°C leads to E-lysis of the 
bacterial cell and yields the empty BGs. 
Fig 1.5: Bacterial Ghosts – Mg-Lysis. The lysis of the bacteria 
leaves the cell devoid of cytoplasm.  
adapted from (Ebensen, Paukner et al. 2004) 
Fig 1.4: Bacterial Ghosts – E-Lysis. Lysing gram negative 
bacteria, showing the expulsion of cytoplasm through the 
lysis hole. adapted from (Tabrizi, Walcher et al. 2004) 
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Applications of BGs 
BGs are used as vaccines themselves, presenting unaltered membrane morphology, membrane bound 
proteins as antigens and furthermore possessing PaMPs (Pathogen associated Molecular Patterns) 
recognized by TLRs and other receptors of the innate immune system and in this way presenting a 
built in adjuvant (Paukner, Kohl et al. 2004; Tabrizi, Walcher et al. 2004; Paukner, Stiedl et al. 2006). 
Antigen proteins of different pathogens may also be expressed in vivo within the membrane complex, 
which makes BG a possible carrier and presenter of multiple native and foreign proteins (fig 1.6). 
 
Furthermore BGs can be used as carrier vehicles for any kind of water soluble molecular structure 
such as proteins, drugs or DNA. BGs are incubated in the drug-, protein- or DNA containing solution 
and in this way loaded with the desired material (Walcher, Mayr et al. 2004).  
In an in situ expression of the desired protein, it can be expressed to integrate into the inner or the 
outer membrane as well as be transported to the periplasmatic space (Paukner, Kudela et al. 2005; 
Kudela, Paukner et al. 2007). This provides a one-step loaded BG production. 
 
 
 
Fig 1.6: Schematic of the localization of different molecules in bacterial ghosts. adapted from (Jechlinger 2005) 
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It has been shown that BGs efficiently target Antigen Presenting Cells (APC) (Paukner, Kudela et al. 
2005). Due to morphological and structural properties such as former mentioned PaMPs BGs are 
readily phagocytosed by Macrophages or Dendritic cells. The uptake of BGs loaded with DNA leads 
to protein expression of the encoded genes (Jechlinger, Azimpour Tabrizi et al. 2004; Paukner, Stiedl 
et al. 2006). 
The SIP (self-immobilizing-plasmid) technique has been established to produce and retain plasmid 
DNA within the bacterial shell after E-lysis in one step (Mayrhofer, Tabrizi et al. 2005).  
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The SIP-technique 
The SIP technique depicts a specially tailored system of plasmid fixation within BGs. SIP stands for 
Self-Immobilizing-Plasmid and describes a method of molecular interaction by using repressor-
operator interaction. 
The SIP plasmid contains, aside other sequences, the ParA recombinase gene with the LacI-L’ gene 
under the shared control of the PBAD-promoter (Szostak, Wanner et al. 1990), which is induced by 
arabinose. The induction of this promoter triggers two reactions: 
 
 The expression of the ParA recombinase, which efficiently catalysis the recombination of the 
motherplasmid, in order to produce minicircle and miniplasmid. 
 
 and LacI-L’anchor protein expression, which is a fusion protein of the L’ anchor (Mayrhofer, 
Tabrizi et al. 2005) and the LacI repressor molecule. The LacI-L’ anchor integrates into the 
inner cell membrane and attaches tightly on the inside of BG. On the other end the protein 
presents the LacI repressor molecule, which ‘finds’ the LacOs operator sequence on the 
minicircle and binds to it (Jechlinger, Azimpour Tabrizi et al. 2004). 
 
The plasmid consists of two parts, secluded by the two recombination sites (described below). The 
antibiotic resistance cassette as well as the origin of replication are, together with the PBAD-controlled 
recombinase and LacI-L’anchor, joined on the part of the motherplasmid, which will form the 
miniplasmid after recombination. Located on the other, the minicircle side, next to the eukaryotic 
expression cassette, which consists of the CMV-promoter, the gene of interest and the BGH-polyA, is 
only the LacOs sequence. By means of molecular interaction the LacI-L’anchor binds to the Lac-Os 
site on the minicircle and fixates it to the inner cell membrane (Jechlinger, Glocker et al. 2005). 
 
This technique combined with E-lysis allows the culturing of bacteria, multiplying the antigen-
encoding plasmid DNA and its recombination into minicircle and miniplasmid as well as the 
generating of BGs by temperature shift (Jechlinger, Azimpour Tabrizi et al. 2004) in one fermentation 
step. The miniplasmid as well as the lysis plasmid, which both lack the LacOs sequence, are lost after 
lysis. As a result the BGs are loaded with minicircle-DNA only (Darquet, Cameron et al. 1997). 
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The Minicircle Technique: 
Definition of the Minicircle 
The term minicircle refers to a small, circular DNA-molecule devoid of any sequences related to 
bacterial origin as first developed by (Darquet, Cameron et al. 1997; Kreiss, Cameron et al. 1998; 
Darquet, Rangara et al. 1999; Bigger, Tolmachov et al. 2001; Chen, He et al. 2003). Minicircles are 
small supercoiled minimal expression cassettes for non-viral gene transfer. 
Disadvantages of using Plasmid DNA as vaccines 
An easy and the most common way to produce high amounts of DNA for DNA-vaccines is plasmid 
propagation and preparation in bacteria. Beside the eukaryotic expression cassette, this method implies 
two distinguished sequences on the desired plasmid, a bacterial origin of replication and a selective 
marker, mostly an antibiotic resistance cassette (fig 1.7). These sequences also reduce efficiency of the 
plasmid in its later use in the host. After selection and propagation they are not needed any further and 
pose a biological safety risk, potentially causing horizontal gene transfer and antibiotic resistance 
distribution within the vaccine recipient. Regulatory agencies therefore recommend, e.g., totally 
avoiding the use of antibiotic resistance genes [FDA, 1996; EMEA, 2001]. Furthermore classical 
plasmid-DNA vectors contain more than 50% bacterial DNA backbone. Therefore the minicircle 
technique is a very efficient way to render slim, efficient and safe DNA agents. It has been shown that 
minicircles, besides there excellent safety profile show improved gene transfer and bioavailability 
properties (Laham 2004). 
Producing Minicircles by Recombination 
Minicircles are produced by site-specific, highly efficient recombination of the motherplasmid (fig 
1.8). The two subsequent circular DNA molecules are the miniplasmid with all undesirable sequences 
as well as the minicircle, which carries beside the expression cassette only half of the recombination 
sites. After recombination the minicircle is kept within the shell of the bacteria by molecular 
interaction, which is described below in detail. The miniplasmid is washed out of the BG. 
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Fig 1.8: Plasmid Recombination. Minicircle and miniplasmid 
(right) are produced (middle) by recombination of 
motherplasmid (left). Due to sequence specific, molecular 
interaction, the minicircle can be separated from the 
miniplasmid. 
adapted from (Jechlinger 2005) 
 
Fig 1.7: Plasmid DNA propagated in bacteria and used for 
eukaryotic gene transfer. It contains sequences related to bacterial 
multiplication as well as eukaryotic expression. The minicircle 
technique is a way to separate the potentially harmful and unwanted 
bacterial sequences rendering efficient and safe minicircles. 
adapted from (Mayrhofer, Tabrizi et al. 2005) 
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RESULTS 
Cloning of pSIP-H5 
Essential for the successful accumulation of the minicircle in the bacterial cell is stringent repression 
of recombination prior to induction. If the plasmid recombines early, a buildup of the self-replicating 
miniplasmid against the non-replicating minicircle in relative numbers would be the consequence.  
Before inserting the H5 gene, the performance of the origin plasmid pSIP-Ova was ensured. 
Plasmid pSIP-Ova: SIP Backbone for Insertion of the H5 Gene 
A -80°C glycerol stock of Firas Al Laham of E.coli K12 strain NM522 (pSIP-Ova, fig 2.1), was used 
for propagation of the plasmid, which serves as the backbone of the pSIP-H5. This plasmid was 
formerly tested and used by Firas Al Laham (Jechlinger, Azimpour Tabrizi et al. 2004; Tabrizi 2005). 
Cloning of pSIP-Ova was performed by Chakameh Azimpour and Wolfgang Jechlinger 
(Champeimont 2007). 
pSIP-Ova includes two resolution sites (RES 1 and RES 2), dividing the motherplasmid into two parts, 
the miniplasmid and the minicircle. On the miniplasmid the Ampicillin resistance cassette and the 
LacI-L’anchor fusion protein as well as the ParA resolvase gene are located. The latter two genes lie 
downstream of the arabinose inducible PBAD-Promoter. Also on this side of the motherplasmid is the 
pUC-origin of replication and the AraC sequence, expressing the PBAD-associated repressor protein. On 
the other side of the resolution sites lies the minicircle. It consists of the eukaryotic expression cassette 
with the IE-CMV promoter and the SV40 polyA sequence; located in between is the Ova-gene, which, 
in former recombination experiments served as control gene for expression. To retain the minicircle 
within the BG after E-lysis, upstream of the IE-CMV promoter is the LacOs sequence. It attaches to 
the membrane bound LacI-L’anchor fusion protein, thus avoiding being expulsed with the cytoplasm 
upon lysis. 
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Western blots targeting LacI and plasmid preparations were used to show the results of LacI-L’anchor 
protein expression as well as ParA recombination. The experiment was designed to show tight 
repression and fast induction of the PBAD promoter. 
Fig 2.1: pSIP-Ova plasmid map. 
amp promoter Ampicillin Promoter LacOs Lac Operator Sequence 
Ara C Ara C Repressor Ova Ovalbumin 
Ara I1I2, Ara O2 AraC regulatory sequences ParA Resolvase ParA Resolvase 
amp promoter ampicillin promoter pbad pbad promoter 
bla ampicillin resistance cassette pUC pUC ori 
CAP_BS catabolite activator protein binding sequence RES 1, RES 2 Recombination sites 
CMV promoter CytoMegaloViral eukaryotic Promoter rrnB_T1, T2, term terminators of 5S ribosomal RNA 
L‘-Anchor+LacI Fusion Protein SV40 PolyA PolyA sequence of simian Virus 40 
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Western blot (fig 2.2) as well as plasmid preparation (fig 2.3) of samples taken at different timepoints, 
confirm expected results. LacI-L’ expression can be seen 15min after arabinose induction. The single 
small band at about 40kDa (lane 0’) is due to genomic LacI expression, which is carried on the 
F’episome. The anti LacI-antibody detects both LacI forms, F’-episomic LacI (39kDa) and plasmid-
derived LacI-L’-anchor fusion protein (45kDa). The different molecular weight of the proteins though, 
allows a clear distinction. 
 
 
 
 
The plasmid preparation shows uncut plasmids. The weak miniplasmid band in the o/n sample 
indicates slight premature recombination; the non proliferating minicircle however is lost during 
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Fig 2.2: Western blot of E.coli K12 strain 
NM522 transformed with pSIP-Ova, targeting 
LacI.  
Each lane represents a different timepoint in 
respect to the defined point 0’ of recombination 
induction with 0,25% Arabinose.  
Fig 2.3: Plasmid Preparation E.coli K12 strain NM522 
transformed with pSIP-Ova of recombination. Each lane 
represents a different timepoint at the stage of recombination. 
Induction took place at timepoint 0’ with addition of 0,25% 
Arabinose.  
genomic LacI (~39kDa) 
 M 0‘ 15‘ 30‘ 45‘ 60‘ 90‘ 
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overnight growth. 30min after arabinose induction the miniplasmid as well as the minicircle band 
appear and grow, whereas the motherplasmid band decreases. 
Plasmid pEPH5: Template for the Amplification of the H5-gene 
The Vietnam Hemagglutinin type 5 gene was located on the pEPH5 plasmid (fig 2.4). This plasmid, 
which provides the antigen in a eukaryotic expression cassette, was provided by LAH, Cuxhaven. 
The H5 gene is located between the T7 promoter and the bovine growth hormone polyA sequence, 
BGH. Also between these regulatory sequences, downstream of the H5 gene lies a Kanamycin 
resistance cassette. Furthermore the plasmid harbors an Ampicillin resistance cassette as well as a 
lacZ_α reporter sequence. Downstream to the Ampicillin resistance cassette lies the pBR322 origin of 
replication.  
 
 
 
 
Fig 2.4: pEPH5 plasmid map. 
bla ampicillin resistance cassette pBR322 ori Origin of Replication 
H5 type 5 Hemagglutinin  polyA, BGH bovine growth hormone polyA sequence 
kan Kanamycin resistance cassette prom Ampicillin Promoter sequence 
Lac Promoter Lac Promoter sequence SP6 prom SP6 polymerase promoter  
lacZ_a reporter lacZ Reporter sequence T7 prom T7 promoter sequence 
loxP loxP site   
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The plasmid was transformed into the E.coli K12 strain NM522. Restriction enzyme analysis of a 
plasmid preparation showed slightly larger bands than anticipated due to plasmid sequence provided 
by LAH. The anticipated 975bp band of the Apa1 restriction (lane1) exceeds the 1000bp band of the 
marker (fig 2.5).  
 
  
 
 
Sequencing of the H5 gene followed cloning of the pSIP-H5 plasmid and showed 62 additional 
unknown base pairs within the eukaryotic expression cassette (fig 2.6). 
TTCGAAATGGAAAAGATCGTGCTGCTGTTCGCCATCGTGAGCCTGGTGAAGAGCGACCAGATCTGCATCGGCTACCACGCCA
ACAACAGCACCGAGCAGGTGGACACCATCATGGAAAAAAACGTGACCGTGACCCACGCCCAGGACATCCTGGAAAAGACCC
ACAACGGCAAGCTGTGCGACCTGGACGGCGTGAAGCCCCTGATCCTGAGGGACTGCAGCGTGGCCGGCTGGCTGCTGGGCAA
CCCCATGTGCGACGAGTTCATCAACGTGCCCGAGTGGAGCTACATCGTGGAGAAGGCCAACCCCGTGAACGACCTGTGCTAC
CCCGGCGACTTCAACGACTACGAGGAACTGAAGCACCTGCTGTCCCGCATCAACCACTTCGAGAAGATCCAGATCATCCCCA
AGAGCAGCTGGTCCAGCCACGAGGCCAGCCTGGGCGTGAGCAGCGCCTGCCCATACCAGGGAAAGAGCAGCTTCTTCCGCAA
CGTGGTGTGGCTGATCAAGAAGAACAGCACCTACCCCACCATCAAGCGCAGCTACAACAACACCAACCAGGAAGATCTGCTG
GTCCTGTGGGGCATCCACCACCCCAACGACGCCGCCGAGCAGACCAAGCTGTACCAGAACCCCACCACCTACATCAGCGTGG
GCACCAGCACCCTGAACCAGAGGCTGGTGCCCAGGATCGCCACCCGCAGCAAGGTGAACGGCCAGAGCGGCAGGATGGAAT
TTTTCTGGACCATCCTGAAGCCCAACGATGCCATCAACTTCGAGAGCAACGGCAACTTCATCGCCCCCGAGTACGCCTACAAG
ATCGTGAAGAAGGGCGACAGCACCATCATGAAGAGCGAACTGGAATACGGCAACTGCAACACCAAGTGCCAGACCCCCATG
GGCGCCATCAACAGCAGCATGCCCTTCCACAACATCCACCCCCTGACCATCGGCGAGTGCCCCAAGTACGTGAAGAGCAACA
GGCTGGTGCTGGCCACCGGCCTGAGGAACAGCCCCCAGCGCGAGAGGCGCAGGAAGAAGCGCGGCCTGTTCGGCGCCATCG
CCGGCTTCATCGAGGGCGGCTGGCAGGGCATGGTGGACGGGTGGTACGGCTACCACCACAGCAACGAACAGGGCAGCGGCT
ACGCCGCCGACAAAGAGAGCACCCAGAAGGCCATTGACGGCGTCACCAACAAGGTGAACTCCATCATCGACAAGATGAACA
CCCAGTTCGAGGCCGTGGGCCGCGAGTTCAACAACCTGGAAAGGCGCATCGAGAACCTGAACAAGAAAATGGAAGATGGCT
TCCTGGACGTGTGGACCTACAACGCCGAGCTGCTGGTGCTGATGGAAAACGAGAGGACCCTGGACTTCCACGACAGCAACGT
GAAGAACCTGTACGACAAAGTGCGCCTGCAGCTGAGGGACAACGCCAAAGAGCTGGGCAACGGCTGCTTCGAGTTCTACCAC
AAGTGCGACAACGAGTGCATGGAAAGCGTGAGGAACGGCACCTACGACTACCCCCAGTACAGCGAGGAAGCCAGGCTGAAG
Fig 2.5: Control Cut of pEPH5: 
expected fragment length: 
 Apa1: 5502bp/975bp 
 BgIII: 5972bp/505bp 
 uc 
 EcoI: 6477bp 
 HindIII: 4014bp/2463bp 
 Sca1: 6477bp 
The supposed 975bp band in the 
second line runs above 1kb. A 62bp 
fragment (fig 2.5) was found by 
sequencing, which was not part of 
the plasmid map provided by LAH. 
marker Apa1 BgIII uc EcoI HindIII Sca1 marker  
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AGGGAAGAGATCAGCGGAGTGAAGCTGGAAAGCATCGGCATCTACCAGATCCTGAGCATCTACAGCACCGTGGCCAGCAGC
CTGGCCCTGGCCATCATGGTGGCCGGCCTGTCCCTGTGGATGTGCAGCAACGGCAGCCTGCAGTGCAGGTGATAATCTAGAG
GGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCATAGGGATAACAGGGTAATCGATTTATTCAACAAAGCCA
CGTTGTGTCTCAAAATCTCTGATGTTACATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTGTCTGCTTACATAA
ACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATGC
TGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATG
CGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGAC
GGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAA
AACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGC
ATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTT
TGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCA
TTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATCTTTGACGAGGGGAAATTAATAGGTTGTATT
GATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATT
ACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTT 
CTAATCAGAATTGGTTAATTGGTTGTAACACTGGCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGAT
CAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTC
CCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGG
CAGGACAGCAAGGGGGAGGATTGGGAAGACAAATGGCCGCATAACTTCGTATAGCATACATTATACGAAGTTATCTAGCATT 
ATAA 
 
 
 
 
The H5 sequence together with the Kanamycin resistance cassette as well as the BGH polyA were 
amplified by PCR, introducing the restriction sites for BstBI (TT|C GAA) and PsiI (TTA| TAA) on 
either end respectively. The PCR product was cut with restriction enzymes BstBI and PsiI and 
purified, using the PCR Purification Kit.  
Cloning of plasmid: pSIP-H5 
The backbone fragment of 6998bp (fig 2.7) of the pSIP-Ova plasmid originates through enzyme 
restriction by BstBI (TT|C GAA) and PsiI (TTA| TAA), cutting out the Ova gene. This vector frag-
ment was ligated with the PCR product of pEPH5 (fig 2.7), resulting in the plasmid pSIP-H5 (fig 2.8).  
 
Fig 2.6: pEPH5 sequence amplified by PCR. 3049bp of pEPH5 were amplified by PCR, introducing the restriction enzyme sites for 
BstB1 and PsiI.  
key:  Vietnam type 5 Hemagglutinin H5 (yellow), SP6 promoter (green), unknown sequence (red), Kanamycin Resistance Cassette (light 
blue), BGH-polyA sequence (purple), introduced sites for restriction enzymes (red letters). 
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Fig 2.7: Ligation Fragments for 
pSIP-H5. The vector fragment 
(6998bp) was produced by double 
digestion (BstBI, PsiI) of pSIP-Ova. 
The pEPH5 originated sequence (H5, 
3049bp) was produced by PCR. 
 
PCR product, H5, 3049bp 
pSIP backbone, 6998bp 
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Cloning strategy of pSIP-H5 
 
Explication of Abbreviations 
Abbrev.  Function  Abbrev.  Function  
aphAI  Kanamycin Resistance Cassette  P
BAD
  arabinose inducible Promoter  
araC  positive and negative Regulator of P
BAD
 Promoter  p
cmv 
 Cytomegalovirus Immediate Early Promoter  
BGH  Bovine Growth Hormone PolyA  p
T7 
 T7 Promoter  
bla  Ampicilline Resistance Cassette  ParA  ParA Resolvase  
LacI-L‘  Membrane anchored (L’) LacI repressor molecule  pBR322-ori Origin of replication 
lacOs  Lac Operator Sequence; LacI Binding Sequence  pUC ori  Origin of Replication  
lacZ lacZ reporter gene Res1 Recombination Site 1  
loxP Bacteriophage P1 derived recombination site Res2  Recombination Site 2  
polyA  SV40 PolyA  rrnB  ribosomal RNA operon 
Ova Ovalbumin gene   
 
fwdSIP-H5 revSIP-H5 
ScaI ApaI EcoRI 
ApaI 
SmaI 
DraIII XbaI FseI 
BamHI EcoRI 
BgIII 
ApaI BamHI 
EcoRI 
EcoRI 
EcoRI 
HindIII 
HindIII 
SmaI 
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After transformation into E.coli K12 strain NM522, the plasmid was control cut and subjected to 
Agarose gel electrophoresis (fig 2.9). 
Fig 2.8: pSIP-H5 plasmid map. The pSIP-H5 was constructed by exchanging the Ova gene, located on the minicircle side of the 
plasmid pSIP-Ova, with the pEPH5 derived H5 gene.  
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8kb 
 
6kb 
5kb 
 
4kb 
3,5kb 
3kb 
 
2,5kb 
 
 
2kb 
 
1,5kb 
 
 
 
1kb 
 
750bp 
 
 
 
500bp 
 
 
 
250bp 
1kb 
marker uc BspEI XbaI Apa1 
Fig 2.9: Restriction enzyme analysis of 
pSIP-H5.  Expected fragment length: 
 BspEI:  10039bp 
 XbaI: 6020bp/4029bp 
 Apa1: 6549bp/2453bp/1037bp 
The additional band in the Apa1 lane 
derives from incomplete digestion. 
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Pre-testings of pSIP-H5 
Transformation of E.coli and Salmonella strains with pSIP-H5 and Storing of 
pSIP-H5 
On Arabinose induction the LacI-L’anchor fusion protein will be expressed as well as the ParA 
Recombinase. Whereas the Recombinase will divide the plasmid into a miniplasmid and a minicircle, 
the membrane anchored LacI-L’anchor fusion protein will, by molecular interaction bind the LacOs 
sequence located on the minicircle, fixing it inside the BG. 
The transformation of plasmid pSIP-H5 into different bacterial strains and its maintenance posed 
unexpected difficulties. The strains used were E.coli K12 strains NM522, DH10beta, Top10, ER2655 
and TB1 as well as the Salmonella strain ATCC 14028. In the Salmonella strain as well as in the 
E.coli K12 strains DH10beta, Top10 and ER2655 the plasmid showed premature recombination (fig 
2.10a&b).  
 
 
 
 
 
 
 
 
10kb 
8kb 
 
6kb 
5kb 
 
4kb 
3,5kb 
3kb 
2,5kb 
 
2kb 
 
1,5kb 
 
 
1kb 
 
750bp 
uncut plasmid 
motherplasmid 
miniplasmid 
Fig 2.10a: Plasmid Preparation of the uninduced (no Arabinose added) overnight cultures 
of E.coli strains ER2566, TB1, DH10β and TOP10 transformed with pSIP-H5. From each 
strain two samples are loaded, which are either uncut or cut with the single cutter BamHI, the 
restriction site is located on the miniplasmid part. Miniplasmid band is visible at 5676bp in 
uninduced overnight cultures of ER2566, DH10β and TOP10. Linearized motherplasmid 
length: 10039bp 
 ER2566 TB1 DH10β TOP 10 
 m uc sc uc sc m uc sc uc sc m uc sc uc sc m uc sc uc sc m 
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Different variations of glucose concentration, growth temperature and growth time combined with the 
purification of the motherplasmid and repeated transformation with the cleaned, unrecombined 
motherplasmid were not successful (fig 2.11).  
 
 
 
 
 
 
 
 
 
 
pSIP-H5 transformed TB1 strain on the other hand does not show the miniplasmid band in the 
overnight cultures. The plasmid preparation of the recombination experiment with TB1 showed late 
and incomplete recombination upon arabinose addition (fig 2.12).  
 
m  1 2 3 4 5 6 7 8 9 m 
 
10kb 
 
6kb 
5kb 
4kb 
3kb 
2,5kb 
2kb 
 
1,5kb 
 
1kb 
 
750bp 
Fig 2.11: Plasmid Preparation of uninduced overnight 
cultures of transformed E.coli strains ER2566, DH10β, 
Top10 and TB1. Strains have been transformed with a 
purified motherplasmid of pSIP-H5 and recombination was 
not induced. For each strain two lanes are loaded with either 
uncut or single cut (BamHI, restriction site located on 
miniplasmid part of motherplasmid) plasmid.  
Miniplasmid fragment length: 5676bp 
Motherplasmid fragment length: 10039bp 
 ER2566 DH10β TOP10 TB1 
uc sc m uc sc uc sc m uc sc uc 
motherplasmid 
miniplasmid 
Fig 2.10b: Plasmid Preparation of the uninduced (no Arabinose added) overnight cultures 
of Salmonella strain ATCC 14028 transformed with pSIP-H5. Lanes 1-9 are different 
clones of Salmonella strain ATCC14028 from the same transformation. The lane marked with 
m signifies the marker. 
miniplasmid 
motherplasmid 
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8kb 
 
 
6kb 
 
5kb 
 
4kb 
 
3,5kb 
 
3kb 
 
2,5kb 
 
 
2kb 
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E.coli K12 strain TB1, for this fact, was used as safe storage for the plasmid, apparently tightly 
suppressing recombination of pSIP-H5. The DNA material later sent to mycrosynth® for sequencing 
was extracted from the TB1 strain, in order to have the most unrecombined motherplasmid possible. 
Only strain NM522 showed a high degree of recombination after arabinose addition together with an 
acceptable repression of premature recombination in the presence of additional 5% glucose. The other 
strains were abandoned from further investigation. 
Small Scale Recombination Experiments 
The strain used for pSIP-H5 minicircle loaded BG production was E.coli K12 strain NM522. Further 
recombination (fig 2.13) experiments were carried out with this strain.  
 m 0’ 15’ 30’ 45’ 60’ 90’ 120’ m 
      motherplasmid 
miniplasmid 
 
 
10kb 
8kb 
 
6kb 
5kb 
 
4kb 
3,5kb 
 
3kb 
 
2,5kb 
 
2kb 
 
1,5kb 
Fig 2.12: Plasmid Preparation of TB1 (pSIP-H5, induced) . 
The timepoints describe minutes after induction of 
recombination by 0,25% Arabinose addition. Miniplasmid 
band first appears 120min after induction, motherplasmid is 
still visible. 
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Cfu counts and OD600 measurements as well as microscopic observations of the fermentation can be 
seen in (fig 2.14 and fig 2.15). Plasmid preparation of certain timepoints as well as western blot 
analysis show appropriate recombination (2.16) and LacI-L’anchor fusion protein expression (fig 
2.17). The LacI-L’anchor fusion protein expression is driven by the same promoter (PBAD) as is the 
expression of ParA resolvase and therefore the successful western blot detection of LacI-L’anchor 
fusion protein also indicates the expression of parA resolvase. 
 
 
 
 
Fig 2.13: Schema of pSIP-H5 recombination.  Upon PBAD induction by 0,25% Arabinose the expressed ParA recombinase will 
recombine the resolution sites (RES1, RES2) present on pSIP-H5; thus producing the pSIP-H5-minicircle and the pSIP-H5 
miniplasmid. Induction of the PBAD promoter also leads to the expression of the LacI-L’anchor fusion protein. The H5-minicircle is 
fixed to the bacterial membrane due to molecular interaction with the membrane bound LacI-L’-anchor fusion protein and the LacOs 
sequence, present on the minicircle. 
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To reach an OD600 of 0,2-0,3, when recombination is induced by addition of 0,25% arabinose, the  
medium inoculated with an amount of an overnight culture to reach an OD600 of 0,07-0,1 took about 
60min. This time window varies slightly. 
 
 
 
 
 
 
Fig 2.14: OD600 measurements and cfu-count of fermentation of 3 E.coli NM522 (pSIP-H5) clones.  The arrow indicates PBAD 
promoter induction by addition of 0,25% Arabinose.  
Fig 2.15: E.coli K12 strain NM522 (pSIP-H5) cells directly before (left) and 100min after 
(right) induction of recombination of pSIP-H5. After induction cells are slightly elongated. 
42 
 
 
 
 
 
 
The time between addition of 0,25% arabinose and the first appearance of the minicircle lies around 
10-20min. After about 1-1,5h of recombination time the motherplasmid band has almost disappeared.  
After 20min the LacI-L’anchor fusion protein band is already clearly visible, which also indicates 
ParA-recombinase expression. 
 
 
  
 
 
 
 
10kb 
8kb 
 
6kb 
5kb 
4kb 
 
3,5kb 
3kb 
 
2,5kb 
 
2kb 
 
1,5kb 
 
 
1kb 
 
0,75kb 
 
 
0,5kb 
 
0,25kb 
 
 
 
 
 
0,25kb 
marker o/n 0‘ 20‘ 40‘ 60‘ 80‘ marker
  
Fig 2.16: Uncut Plasmid Preparation (pSIP-H5) 
of recombination experiment. Each lane shows a 
different timepoint, the units are minutes after 
recombination induction with 0,25% Arabinose. 
motherplasmid, 10039bp 
miniplasmid, 5676bp 
minicircle, 4363bp 
 0‘ 20‘ 40‘ 60‘ 80‘ marker 
50kDa 
 
 
 
40kDa 
 
 
30kDa 
 
 
 
25kDa 
 
 
20kDa 
LacI-L’anchor  (~45kDa) 
genomic LacI (~38,8kDa) 
Fig 2.17: Western blot of different 
timepoints of fermentation of E.coli strain 
NM522 (pSIP-H5). The antibody targets 
the LacI. Each lane represents a different 
timepoint in respect to the 0’ point of 
recombination induction with 0,25% 
Arabinose. 
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Pretestings of pSIP-H5 and pGLysivb double Transformants of 
E.coli K12 strain NM522 
Lysis plasmid pGLysivb 
For the induction of E-lysis to produce E.coli K12 strain NM522 BGs plasmid pGLysivb was used (fig 
2.18). 
 
Fig 2.18: pGLysivb plasmid map. 
Eivb Lysis Gene E from Bacteriophage ΦX174, with  
  additional in vivo biotinylation sequence. 
ori Origin of Replication, rep 
gent Gentamycin Resistance Cassette RBS, SD Ribosome binding site, Shine-Dalgarno Sequence 
lac prom lac promoter Repressor cI857 temperature sensitive Repressor for λpR Promoter 
lacZ_a lacZ_α reporter sequence T3 promoter bacteriophage T3 promoter sequence 
mob mobilization sequence (Barlett P 1950) T7 promoter bacteriophage T7 promoter sequence 
OR1, 2, 3 partitioned λpR Promoter   
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The plasmid pGLysivb was used for its well-investigated properties and its overall lysis efficiency of 
more than 99,7% (Jechlinger, Szostak et al. 1999). The Eivb lysis gene, derived from Phage ΦX174 is 
under the control of the temperature sensitive -Pmut-Promoter. This promoter is tightly repressed by 
the thermally instable interaction with the gene product of the repressor cI857 at the bacterial growth 
temperature of 36°C and active at 42°C (Standardization 2007), thus enabling propagation of the lytic 
protein. The selective marker is a Gentamycin resistance cassette.  
Successful transformation of E.coli K12 strain NM522 with the plasmid pGLysivb is shown on one 
hand by growth on selective antibiotic agar plates and as well by plasmid preparation (fig. 2.19 a and 
b).  
Transformation of E.coli K12 strain NM522 with pSIP-H5 and pGLysivb 
MOPS competent E.coli K12 strain NM522 was transformed simultaneously with pSIP-H5 and 
pGLysivb, growing cultures on selective plates and clones were picked. Plasmid preparation showed 
corresponding bands (fig 2.19 a and b), further investigations combining recombination and lysis were 
carried out.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10kb 
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5kb 
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1,5kb 
marker uc BamH1 Sma1 
Fig 2.19a: Restriction Enzyme 
Analysis of E.coli NM522 
transformed with pSIP-H5 
and pGLysivb. 
pSIP-H5  motherpl. minipl. minicircle 
BamHI 10039bp 5675bp uncut 
Smal 10039bp uncut 4364bp 
 
pGlysivB  
BamHI 4768bp/1433bp 
SmaI 6201bp 
pGLysivb band  (uncut) 
and pSIP-H5 miniplasmid 
(uncut) band are close 
 
pGLysivb (cut) 
 
 
miniplasmid (uncut) 
minicircle (cut) 
 
 
 
 
 
 
 
pGLysivb (doublecut) 
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1,5kb 
marker uc BamH1 Sma1 
Fig 2.19b: Restriction Enzyme 
Analysis of E.coli NM522 
transformed with pSIP-H5 
and pGLysivb: 
pSIP-H5  motherpl. minipl. minicircle 
BamHI 10039bp 5675bp uncut 
Smal 10039bp uncut 4364bp 
 
pGlysivB  
BamHI 4768bp/1433bp 
SmaI 6201bp 
 
motherplasmid (cut) 
 
miniplasmid (cut) 
pGLysivb (doublecut) 
 
 
minicircle (uncut) 
 
 
 
 
 
 
pGLysivb (doublecut) 
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For the restriction enzyme analysis the plasmids were prepared from a recombination experiment, 
which consisted of motherplasmid as well as recombined plasmid. This way the unrecombined as well 
as the recombined state of pSIP-H5 can be seen.  
Recombination of pSIP-H5 and Lysis Experiment 
Fermentation of E.coli K12 strain NM522 transformed with pSIP-H5 and pGLysivb was carried out. 
OD600 measurements and cfu diagram can be seen in fig 2.16. 
 
 
 
 
 
 
 
The time window from inducing recombination of pSIP-H5 to activating E-lysis was 1h. To ensure a 
stable concentration of arabinose another addition of the same amount (375µl of 20% arabinose for 
30ml medium) was applied 30min after the first to clone 3 and 4. 
About 20 minutes after the time of activation of the pGLysivb by a temperature shift from 36°C to 
42°C, corresponding to 1h after induction of recombination of pSIP-H5, cfu-count drops, followed by 
Fig 2.20: OD600 measurements and cfu-count of four different E.coli K12 strain NM522 (pSIP-H5) clones.  The 
arrows indicate addition of 0,25% Arabinose (induction, 2nd induction) to induce recombination of pSIP-H5. A second 
addition of Arabinose was applied only to clone 3 and 4. Temperature shift from 36°C to 42°C activating E-lysis by 
induction of the temperature sensitive -Pmut-promoter controlling the expression of the Eivb on pGLysivb is also 
indicated by an arrow.  
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a drop of OD600 measurements about 40min later. The cfu curve shows an average lysis efficiency of 
99,992%. 
 
 
 
 
 
 
 
In the left picture E.coli cells can be seen before activation of pGLysivb by temperature shift from 
36°C to 42°C. In the right picture the microscopy sample was taken 180 minutes after temperature 
shift displaying BGs. Plasmid pSIP-H5 recombination and expression of LacI-L’anchor were observed 
by plasmid preparation and western blotting (figs 2.22 and 2.23). 
 
 
 
 
 
 
 
 
 
 
10kb 
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6kb 
5kb 
 
4kb 
3,5kb 
 
3kb 
 
2,5kb 
 
2kb 
 
 
1,5kb 
Arabinose Addition Temperature Shift 
Recombination  Lysis Induction 
Induction 
 marker -60‘ -30‘ 0‘ 20‘ 40‘ 60‘ 90‘ 120‘ 180‘ marker  
Fig 2.22.: Uncut Plasmid Preparation of E.coli K12 
strain NM522 (pSIP-H5, pGLysivb). The arrows indicate 
the addition of 0,25% Arabinose inducing the recombination 
of pSIP-H5 as well as the expression of the LacI-L’anchor 
fusion protein. Also the Temperature shift from 36°C to 
42°C is indicated by an arrow. The lanes show different 
timepoints of the fermentation, [min in respect of 
temperature shift (at 0 minutes)]. 
 motherplasmid 
pGLysivb 
miniplasmid 
minicircle 
Fig 2.21: E.coli K12 strain NM522 cells harboring pSIP-H5 and pGLysivb before and after 
E-Lysis induction. The left picture shows the cells 60min after recombination induction of 
pSIP-H5 by an addition of 0,25% Arabinose and immediately before lysis induction. The right 
picture shows BGs 180min after E-Lysis induction by temperature shift from 36°C to 42°C. 
Cells after lysis induction are transparent.  
BGs 
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The first slight minicircle band can be seen 30min after induction of recombination of pSIP-H5. Also 
the sample of -60min (lane 2) shows a faint miniplasmid band, which points to recombination of pSIP-
H5 already in the o/n culture.  
 
 
  
 
 
 
In the western blot the first LacI-L’anchor fusion protein band (~45kDa) is visible 30min after 
addition of 0,25% arabinose (lane 3, tp -30’). After the second addition of 0,25% arabinose (lane 4, 0’) 
the band appears stronger. Also the genomic LacI is visible at the time of arabinose addition and at -
30’ but vanishes later on.  
Fermentation of E.coli strain NM522 (pSIP-H5, pGLysivb) 
Fermentation Process 
Two clones of E.coli K12 strain NM522 harboring pSIP-H5 and pGLysivb were disponible for 
fermentation in the 30l bioreactor. The state of recombination of plasmid pSIP-H5 of different 
glycerin stocks was tested by restriction enzyme analysis, to decide with which clone to carry on (fig 
2.24). 
 
marker -60‘ -30‘ 0‘ 20‘ 40‘ 120‘ 180‘ marker 
50kDa 
 
 
40kDa 
 
30kDa 
 
 
25kDa 
 
20kDa 
LacI-L’anchor  (~45kDa) 
genomic LacI (~38,8kDa) 
Fig 2.23: Western blot of a fermentation of E.coli K12 
strain NM522 harboring pSIP-H5 and pGLysivb targeting 
LacI. Each lane represents a different timepoint in respect to 
the 0’ point of E-lysis induction by temperature shift to 42°C. 
At timepoint -60’ 0,25% of Arabinose were added, inducing 
the recombination of pSIP-H5 as well as the expression of the 
LacI-L’anchor. 
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Clone 6 shows only the 10039bp band of the unrecombined motherplasmid of the pSIP-H5, clone 3 
also shows a slight miniplasmid band at 5675bp, which indicates uninduced recombination of pSIP-H5 
in the o/n culture. For these reasons clone 6 was chosen for the large scale fermentation. 
Inoculation culture showed an OD600 of 0,981, the 1:10 dilution showed an OD600 of 0,122. After 
inoculation of the fermenter, the medium within the fermenter showed an OD600 of 0,05. The 
fermentation process was closely observed by the IRIS program (fig 2.25).  
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5kb 
 
4kb 
 
3,5kb 
 
3kb 
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1,5kb 
 clone3 clone6 
marker BamH1 uc BamH1 uc marker 
motherplasmid, 10039bp 
 
Fig 2.24: Restriction Enzyme Analysis of two clones of E.coli K12 
strain NM522 harboring the plasmids pSIP-H5 and pGLysivb. 
Clone 3 shows a slight miniplasmid band. No miniplasmid band is 
visible in the lane of clone 6.  
Expected fragment length: 
pSIP-H5  motherplasmid miniplasmid minicircle 
BamHI 10039bp 5675bp uncut 
pGlysivB  
BamHI 4768bp/1433bp 
 
 
miniplasmid, 5675bp 
pGLysivb, 4768bp fragment 
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The IRIS diagram shows pH-value, Oxygen concentration, airflow-rate, stirring per minute and 
temperature. After three hours of fermentation, at an OD600 of 0,6 0,25% arabinose was added, 
inducing the PBAD promoter and thus the expression of ParA recombinase as well as the LacI-L’anchor 
fusion protein. pH is stable as is the temperature and the air flow. The stirring frequency increases 
steadily to keep pO2 above 5%. The value of the partial Oxygen pressure indirectly corresponds to the 
growth of the culture metabolizing Oxygen. About 30 minutes after lysis induction the pO2 value starts 
to rise, pointing to the dying of the bacteria. 90 minutes after induction of lysis surviving cells are 
killed with antibiotics. 
Further observation of fermentation can be found in fig 2.26. 
 
NM522pSIP-H5-Ghosts 
Date: 29.11.2007   Clone: 6 (21.09.07) 
Starting time: 9:00   Strain: NM522 
End time: 19:00   Plasmids: pGLysivb, pSIP-H5 
ON culture OD: 
0,981(pure)/0,122(diluted 1:10)   
Recombinant Protein Expression: LacI-L’anchor / 
ParA Recombinase 
Inoc. Volume: 2 L   Expression Induction: 0,25% arabinose  
Medium: LBv   Expression Induction Timepoint: G 
Antibiotics: Gent + Amp   Lysis Induction: 42°C 
Temperature: 35°C   Lysis Induction Timepoint: I 
Total Volume: 22 L   Killing: Strep / Tet (L) 
Acid: F.A.: 0ml  Volume harvested: ~20l 
Base: A.W.: 0ml  Harvested by: Separator, washing H2O and 0,5mM saline 
Antifoam A: 0ml  OD separator flowthrough: 0,11 / 0,063/0,053/0,047 
E-Blot: not performed  Yield: 1070mg 
R-Blot: OK (by MRA)  Particles / mg: 7,57E08 (ww); 2,41E08 (sw) 
Fig 2.25: Observation of the fermentation of E.coli K12 strain NM522 harboring pSIP-H5 and pGLysivb. Recombination of pSIP-
H5 was induced by addition of 0,25% Arabinose after three hours of fermentation. E-Lysis induction by temperature shift followed one 
hour later after 4h of fermentation. The final killing of all bacteria was carried out by addition of antibiotics. Curves show temperature 
[°C](yellow), stirring frequency [1/min](red), pH value (green), air flow [l/min](purple) and partial Oxigen pressure [%](blue). 
50 
 
RT:   Sterility: OK by AFA 
Microscopy: ghosts  Efficiency: 99,92% 
 
timetable 
Time Minutes Sample Microscopy OD OD 1/10 pH Flow/pO2 rpm Temp 
 
 
 ON  0,981 0,122     
11:00 
 
-240’ A  0,05  7,2 12 120 35°C 
11:30 
 
-210’ B alive; elongated 0,165  7,2 12 120 35°C 
12:00 
 
-180’ C  0,21  7,2 12 120 35°C 
12:30 
 
-150’ D alive; elongated 0,32  7,2 12 120 35°C 
13:00 
 
-120’ E  0,382  7,2 12 140 35°C 
13:30 
 
-90’ F  0,451  7,2 12 160 35°C 
14:00 
 
-60’ G nice, short cells; elongated cells in 
minority   0,58 
 7,2 12 180 35°C 
14:40 
 
-30’ H OK 0,65  7,2 12 220 
 
35°C 
15:00 
 
0’ I single dead cells  
OK  
0,853 0,109 
7,2 12 240 42°C 
15:30 
 
30’ J ghosts 0,766 0,089 7,2 12 280 42°C 
16:00 60’ K ghosts 0,578 0,07 7,2 12 280 42°C 
16:30 90’ L OK 0,533 0,068 7,2 12 280 42°C 
16:45 105’ M  0,562 0,06 7,2 12 280 42°C 
17:00 130 N  0,563 0,064 7,2 12 280 42°C 
17:15 145 O  0,494 0,06 7,2 12 280 42°C 
17:30 160 P  0,514 0,059 7,2 12 280 42°C 
 
Notes: 
arabinose (0,25%) was added to the vessel at the time point G. 
Lysis was induced by temperature upshift to 42°C at timepoint I. 
RT samples (2x) were taken every time point (starting from B) and stored at -80 °C. 
20l were treated with Streptomycin and Tetracycline (double dose) for 60 min (samples were taken at the point 0’ and then 
every 15 min). 
WB samples were taken every time point starting from B to the end of process except M and O.  
____________________________________ 
fig 2.26: Fermentation-report 
The overall growth of E.coli K12 strain NM522 was observed by OD600 measurements and cfu count 
(fig 2.27). 
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Qualitiy Control of large scale Fermentation 
To confirm recombination as well as expression of the LacI-L’anchor, lysis and bacterial appearance, 
the results of microscopic observation (fig 2.28a&b), plasmid preparation (fig 2.29) and western blot 
targeting LacI (fig 2.30). 
 
 
 
 
 
 
Fig 2.27: OD600 measurements and cfu count of fermentation of E.coli K12 strain harboring pSIP-H5 and 
pGLysivb. After 3 hours of fermentation 0,25% Arabinose were added (arrow) inducing recombination of pSIP-H5. 
After 4 hours of fermentation E-Lysis was induced (arrow). After 90 minutes of lysis, surviving cells were killed by 
antibiotic addition. 
Fig 2.28a: E.coli NM522 cells harboring pSIP-
H5 and pGLysivb. At 30 minutes before 
recombination induction. 
Fig 2.28b: E.coli NM522 BG harboring pSIP-H5 
and pGLysivb. 90 minutes after lysis induction. 
Cells are slightly elongated, pale appearance. 
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The miniplasmid and minicircle band appear at the timepoint -30 minutes, 30 minutes after PBAD 
activation by arabinose induction. Due to the very similar molecular weight of miniplasmid and 
pGLysivb the two bands cannot be kept apart without restriction enzyme digest. After 220min the 
motherplasmid band has almost vanished, thus leaving only miniplasmid and minicircle, a sign of 
efficient recombination. However, after lysis the miniplasmid is still present and apparently not fully 
washed out of the ghost. A former fermentation product washed with ddH2O did not show sufficient 
extraction of the remaining miniplasmid, therefore the harvested material was divided and either 
washed with water or with 500mM saline, to extract the remaining miniplasmid from the shell (fig 
2.27). 
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induction of recombination induction of lysis  
 
marker o/n -60’ -30’ 0’ 60‘ 90‘ 120‘ marker  
Fig 2.29: Plasmid preparation at different 
timepoints of fermentation of E.coli K12 strain 
NM522 harboring pSIP-H5 and pGLysivb. The 
o/n bands appear stronger due to dilution differences. 
After 4 hours of fermentation (0’) E-lysis is induced 
by temperature shift of 36°C to 42°C. Miniplasmid 
and minicircle bands appear about 30 minutes (-30’) 
after addition of 0,25 Arabinose, inducing 
recombination of pSIP-H5 
pGlysivb 
unrecombined 
motherplasmid 
miniplasmid 
minicircle 
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The western blot shows LacI-L’anchor expression 60min after arabinose addition, which corresponds 
to 4 h of fermentation. With the expression of the LacI-L’anchor the pSIP-H5 minicircle is fixated 
within the bacterial shell and kept from expulsion.  
Washing of the BGs 
 
 
 
 
 
 
Harvested ghosts were washed either with water or with saline (500mM). Solubility of the BGs in 
saline was far less than in water. Plasmid Preparation shows bands of the minicircle as well as the 
miniplasmid (fig 2.31). The expected result was for the saline washed BGs to contain less miniplasmid 
due to favoured extraction of randomly bound miniplasmid to LacI-L’anchor fusion protein bound 
minicircle.  
 
 induction of   induction of lysis 
 recombination 
 marker -60‘   -30   0‘ 30‘ 60‘   90’ 120’ marker 
50kDa 
40kDa 
30kDa 
25kDa 
20kDa 
LacI’-L anchor (~45kDa) 
Fig 2.30: Westernblot of fermentat-
ion of E.coli K12 strain NM522 har-
boring pSIP-H5 and pGLysivb.  The 
antibody targets LacI. Each sample is 
taken at a different timepoint in respect 
to the 0min point of lysis induction. 
Recombination of pSIP-H5 is induced 
60 minutes before lysis. 
10kb 
8kb 
 
6kb 
5kb 
 
4kb 
 
3,5kb 
3kb 
marker ww sw 
Fig 2.31: Plasmid Pre-
paration of BGs. The 
harvested BGs were either 
water-washed (ww) or 
saline-washed (500mM) 
(sw).  
miniplasmid 
 
minicircle 
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Quantification of minicircle DNA using realtime-PCR 
Realtime-PCR Standard targeting pSIP-H5 minicircle 
After unsuccessful tries to extract clean minicircle from purifying agarose gel as a standard for the rt-
PCR, purified, unrecombined motherplasmid was used instead, taking into account a molecular weight 
relation of 0,4284. Plasmid preparation of the E.coli K12 strain TB1, which was formerly transformed 
with pSIP-H5 and had shown very tight repression of recombination, was control cut (fig 2.32) to 
confirm plasmid status. The DNA concentration in the preparation was evaluated by OD260/280 
measurement and used as rt-PCR standard. Primers used were fwdLacOs [5’-gac ttc gaa atg gaa aag 
atc gtg ctg-3’] and revLacOs [5’-ata aca tta taa tgc tag ata act tcg tat aa-3’].  
 
 
 
 
 
 
 
 
Although this plasmid preparation shows a slight miniplasmid band in the BamH1 lane, it was used as 
rt-PCR standard. A control rt-PCR was carried out with the standard preparation alone in different 
dilutions (fig 2.33). 
10kb 
 
8kb 
 
6kb 
 
5kb 
 
4kb 
 
3,5kb 
 
3kb 
 
2,5kb 
 
2kb 
marker uc BamH1 Sma1  
Fig 2.32: Restriction Enzyme 
Analysis of  pSIP-H5. Preparation 
of pSIP-H5 of E.coli K12 strain 
TB1 for PCR standard. 
 motherplasmid mp 
BamH1: 10039bp  5675bp
 minicircle remains uc  
 motherplasmid  mc 
Sma1: 10039bp  4363bp 
 miniplasmid remains uc 
motherplasmid, 10039bp 
 
miniplasmid, 5676bp 
 
no minicircle 4363bp 
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The outcome of the control rt-PCR of the pSIP-H5 standard dilution series shows a correlation 
coefficient of 0.995 and a PCR efficiency of 113.5%. The length of the PCR product was further 
checked by agarose gel electrophoresis (fig 2.34). 
 
 
 
 
 
 
 
 
 
Fig 2.33: BioRad® iCycler rt-PCR process observation. Realtime PCR-run of standard dilutions. Targeted sequence was 
LacOs, situated on the minicircle part of the motherplasmid pSIP-H5 (DNA used: motherplasmid, pSIP-H5). 
Above: Graph: Amplification per cycle. For each concentration two wells were used.  
Below: Standard curve with a correlation coefficient 0,995. 
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The gel electrophoresis shows the band at 233bp in all samples. The preparation was used to create a 
standard curve based on dilution series, to be able to quantify the amount of minicircle loaded in the 
BGs. 
rt-PCR using BGs as sample 
To quantify the amount of propagated and fixated minicircle within the BGs, a realtime PCR was 
carried out, targeting the LacOs sequence, which is present on the minicircle (and the motherplasmid). 
Subjected to the rt-PCR were whole BGs loaded with pSIP-H5 minicircle, from both water washed as 
well as saline washed harvested material (2.31). 
Following can be found the documentation of the iCycler rt-PCR observation (2.35).  
 
Fig 2.34.: rt-PCR product of pSIP-H5 
targeting LacOs sequence. Different 
dilution series for standard curve in 2% 
Agarose gel.  
3kb 
2,5kb 
 
2kb 
 
1,5kb 
 
 
1kb 
 
750bp 
 
 
500bp 
 
 
 
 
250bp 
 
rt-PCR Product, 233bp 
Fig 2.35: rt-PCR of pSIP-H5 minicircle loaded BGs, targeting the LacOs sequence. Different 
lines show standard curve samples as well as BG samples of unknown minicircle DNA 
concentration.  
m different rt-PCR dilutions m 
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The threshold is set by the program itself, calculating the intersection which produces the highest 
correlation coefficient of the functions in order to get the most accurate standard curve (fig 2.36), 
rendering samples below the threshold invalid.  
 
 
 
 
The Correlation Coefficient is 0,996, the PCR efficiency is 130%. The melting curve can be found 
below (fig 2.37). 
 
 
 
 
Agarose gel electrophoresis of the standard curve dilution samples as well as of the BG-samples 
loaded with pSIP-H5 minicircle shows bands at 233bp (fig 2.38). 
 
Fig 2.37: Melting curve of rt-PCR targeting LacOs sequence of BGs loaded with pSIP-H5 
minicircle. Samples are the standard dilutions as well as BGs loaded with an unknown minicircle 
concentration. 
Fig 2.36: Standard curve of rt-PCR targeting LacOs sequence. Whereas the blue 
circles show the standard dilutions, the red squares depict the Unknowns, which are 
also applied in dilutions. 
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PCR was positive for all tested samples, water washed (lanes 1-6) and saline washed (lanes 7-12) 
alike. 
The calculated amount of minicircle fixated in the BG based on the results of the rt-PCR lies between 
44,7µgDNA/mg lyophilised material for water washed BG and 3,2µgDNA/mg lyophilised material for 
saline washed BG (2.39). 
 
 
 
 
6kb 
4kb 
3kb 
 
2,5kb 
 
2kb 
1,5kb 
 
1kb 
 
0,75kb 
 
 
0,5kb 
 
 
0,25kb 
marker 1 2 3 4 5 6 7 8 9 10 11 12 neg neg 
Fig 2.38: 2% Agarose Gel of rt-PCR of BG-samples. The amplified 
LacOs sequence is 233bp long. Lanes 1-6 show rt-PCR samples of water-
washed BGs whereas lanes 7-12 show saline washed BGs. 
rt-PCR product, lacOs, 
233bp 
primers 
Fig 2.39: Amount of minicircle per single BG. Bars represent amount of minicircle molecules per 
saline (500mM) washed BG in contrary to water washed BG. 
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Sterilizing Process after Fermentation 
Standard Sterilizing Procedure 
Safety guidelines for biotechnology products proposed by the WHO demand a reliable prevention of 
any bacterial growth, infectivity (in case of conventional vaccine production) or other form or 
possibility of DNA propagation in biotechnology products (Lubitz 2008). The killing-efficiency of E-
lysis in E.coli ranges up to about 5 logs. Several different methods are in use of achieving total 
inactivation. Besides the snuc-technique (recombinant in situ expression of staphylococcal nuclease) 
(Morgeaux 1995) and different antibiotics, β-Propiolactone (BPL) (fig 2.40) poses a consistent 
possibility of deactivating any further growth or propagation. Easily hydrolyzed in aqueous 
environment, it is a strongly alkylating agent, which interacts with nucleic acids, proteins and any 
other nucleophilic reagent (Savel’ev 1966; Pedreira and Tauraso 1969; Daly, Orszulak et al. 1991; 
Brault, Bouilly et al. 1996; Scheidler, Rokos et al. 1998; Brault, Renault et al. 1999; Stittelaar, Boes et 
al. 2000). BPL is widely used as disinfecting agent from sterilizing cultivation apparatus for 
microorganisms over plasma sterilization of blood and tissue transplants to vaccine production 
(Mayrhofer, Tabrizi et al. 2005).   
 
 
 
 
Fig 2.40:  Mode of action of β-Propiolactone 
Above: general mode of β-Propiolactone reaction on nucleophilic reagents. 
 Below: Alkylation of Guanin residue.  adapted from [Barlett, P., 1950] 
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The mode of action and the impact of this agent on DNA highly depend on applied concentration and 
temperature and reaches from weak alkylation of mostly Guanine residues to complete destruction of 
nucleosides leaving only the phosphate-backbone unharmed. Due to its relative instability the effect of 
BPL itself is very transitory, and after hydrolization it completely loses its toxicity, rendering beta-
hydroxy-propionic acid (fig 2.40). 
The concentration used for final bacterial inactivation of the fermentation broth is 0,0375%; this dose 
of 7,5ml BPL (20l culture) is added twice with a 30 minutes time gap at the end of fermentation. 
Decrease in DNA Quality through the Use of β-Propiolactone 
Only a few applications of BGs involve the later on-use of DNA within the BG. It was found that for 
the in vivo loading of BGs with pSIP-H5 minicircle, the use of BPL as killing agent is not suitable due 
to DNA decrease (fig 2.41). 
 
 
 
 
 
 
 
 
 
 
BPL-DNA Interaction Experiment 
Since these findings were not anticipated, questions were raised on whether the decrease is a direct 
effect of the BPL or rather a result of other factors on BPL-treated DNA. The conjecture is that 
bacterial enzymes are responsible for the degradation of DNA treated with BPL in this distinct 
concentration. To prove this hypothesis a DNA preparation was incubated with sterile-filtered medium 
time after lysis induction: 
  100’ 130’ 160’ 130’ 160’  
marker H IAB JAB Iβ Jβ 
Fig 2.41: Plasmid Preparation pSIP-H5 minicircle loaded 
BGs of fermentation terminated by BPL- and antibiotic 
addition respectively. 
Plasmid Preparation of fermentation of E.coli K12 strain 
NM522 transformed with pSIP-H5 at different timepoints. 
At timepoint I (after 130’ of fermentation) culture was split 
and different inactivation methods was applied (AB 
indicates inactivation with Antibiotic (Strep/Tet), β indicates 
BPL respectively).  
decreasing DNA 
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of different fermentation timepoints (before and after lysis) and BPL was added. The DNA again was 
retracted and checked by agarose gel electrophoresis (fig 2.42). 
 
 
 
 
 
 
 
 
It was found that before Lysis, where the medium is mainly free of any cytoplasmic content (i.e. 
enzymes), the BPL alone does not have any influence on the length of the DNA (lanes L). Although 
there is a difference in band pattern to the original DNA (lane P), the molecular weight of the DNA is 
not greatly influenced. On the contrary, 2h after induction of Lysis (at the time when antibiotic was 
added), i.e. the medium now carries much cytoplasm expelled from bacteria, the degradation of DNA 
is obvious. After 45’ no more DNA can be found on the gel. 
The conclusion is, that BPL alone in the concentration used (0,04%) does not harm DNA directly (lane 
L), but rather renders it subject to enzymatic degradation by bacterial enzymes (lanes 0’ to 60’). In any 
case, for our purposes of generating pSIP-H5 minicircle harboring E.coli BGs, BPL is no useful 
inactivation agent due to uncertain interference with DNA ranging from alkylation of Guanin residues 
to breakdown of the Pphosphate-ribose backbone. 
 m P L 0’ 15’ 30’ 45’ 60’ m L 0’ 15’ 30’ 45’ 60’ m L 0’ 15’ 30’ 45’ 60’ m 
Fig 2.42: DNA Preparation (pUC18) after being incubated with β-Propiolactone in 
sterile filtered cultivation medium. The different lanes represent different fermentation 
timepoints at which the medium for incubation is taken from the fermenter (fermentation of 
E.coli NM522 (pSIP-H5 and pGLysivb)) and sterile-filtered; β-Propiolactone was added 
and this medium then was used to incubate with the DNA preparation. L corresponds with 
the timepoint of Lysis induction (immediately before), whereas the minute indications 
correspond to time after Sterilization with Antibiotic. 
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Discussion 
Overview 
The aim of this work was the construction of the pSIP-H5 plasmid out of the pSIP-Ova and the pEPH5 
plasmid, transform it into a suitable host bacterium, perform E-lysis and thus obtain BGs loaded with 
pSIP-H5 minicircle in a one-step fermentation. The BGs loaded with the minicircle, which harbors a 
eukaryotic H5-expression-cassette, consequently function as carrier for a DNA vaccine against Avian 
Influenza Virus type H5N1 for poultry. 
Several steps led to this object and are here discussed separately. 
 
 Construction of the plasmid pSIP-H5 
 Transformation of the plasmid pSIP-H5 into a suitable host bacterium 
 Transformation of the plasmid pGLysivb into the pSIP-H5 carrying strain 
 Fermentation of E.coli K12 strain NM522 (pSIP-H5, pGLysivb) in the 30l bioreactor to 
produce pSIP-H5 minicircle loaded BGs for cell culture or animal testing 
 Quantification of pSIP-H5 minicircle molecule per BG 
Construction of the plasmid pSIP-H5 
The amplification product of the H5 gene, derived from the pEPH5 plasmid, by PCR was sent to 
Mycrosynth®, Switzerland, for sequencing.  The result showed 62bp not documented in the sequence 
provided by LAH, Germany (fig 2.6). The additional 62bp are found in a non-coding region and did 
not have any measurable effect on constructing the plasmid pSIP-H5 (fig 2.8). What effect this might 
have on the expression of the H5 gene in targeted eukaryotes can only be investigated by cell-culture- 
or animal tests. Furthermore two single-cut restriction enzyme sites were introduced with the 
amplification, BstBI and PsiI (fig 2.8). The properties of pSIP-Ova (fig 2.1), from which the SIP 
backbone (Laham 2004; Mayrhofer, Tabrizi et al. 2005) derives, were tested in growth, expression of 
the ParA as well as the LacI-L’anchor fusion protein and recombination (figs 2.2, 2.3) before the OVA 
gene was replaced by the H5 gene. Expression of the LacI-L’anchor fusion protein, controlled by the 
PBAD promoter occurs about 30 minutes to one hour after induction by arabinose (fig 2.2).  Also the 
efficiency of recombination of pSIP-H5 by parA resolvase is confirmed by plasmid preparation. No 
motherplasmid could be detected 70 minutes after induction of recombination (fig 2.3). These findings 
are comparable to former publications (Laham 2004). 
63 
 
After the insertion of the H5 gene into the SIP backbone and transformation of the plasmid into E.coli 
K12 strain NM522 a restriction enzyme analysis showed slightly larger bands than anticipated due to 
the sequence provided by LAH (fig 2.5). The reason was the 62bp fragment found in sequencing. 
Transformation of the plasmid pSIP-H5 into a suitable host bacterium 
After transformation of pSIP-H5 into several different E.coli and Salmonella strains plasmid 
preparation showed premature recombination in the E.coli strains ER2566, DH10β and Top10 (fig 
2.10a) as well as in the Salmonella strain ATCC 14028 (fig 2.10b). Several different setups of glucose 
concentration and growth time could not repress the PBAD promoter tightly in these strains (fig 2.11). 
As a consequence the strains ER2566, DH10β and Top10 as well as the Salmonella strain ATCC 
14028 were abandoned from further investigations. No previously generated data on those strains in 
relation to SIP-plasmid performance was accessible. E.coli K12 strain TB1 showed no premature 
recombination but very long response time to PBAD activation. Recombined miniplasmid or minicircle 
could first be detected 120 minutes after induction by arabinose (fig 2.12). TB1 was also abandoned 
from fermentation and BG production but used as a storage strain for pSIP-H5. The sequence sent to 
Mycrosynth®, Switzerland was prepared from this strain.  
After successful transformation of pSIP-H5 into the E.coli K12 strain NM522 recombination (fig 2.13) 
and LacI-L’anchor fusion protein expression were tested again. No difference to the pSIP-Ova results 
was found. Plasmid preparation over time shows recombination 20 minutes after induction with 
arabinose, motherplasmid could not be detected after 80 minutes of recombination time, pointing to 
complete recombination (fig 2.16). Formerly generated data indicates recombination completion 
already 15, 20 or between 20 and 40 minutes after arabinose induction (compare (Jechlinger 2005) 
[pSIP-Ova, pSIP-CafI, pSIP-PA and pHCNparA respectively]).  
Western blot analysis shows LacI-L’anchor fusion protein expression 40 minutes after induction by 
arabinose (fig 2.17). The time difference after induction of recombination onset (20 minutes on the 
plasmid preparation) and LacI-L’anchor fusion protein expression (40 minutes on western blot) has to 
be found in the different techniques of detection, since recombination can only take place after parA 
recombinase expression, which is tightly connected with LacI-L’anchor expression (fig 2.8). 
Comparison of these findings with former data could not be made due to different time resolution in 
sample taking (Champeimont 2007). 
Data on growth of the culture observed by OD600 as well as cfu count can be found in (fig 2.14). 
Activation of the PBAD promoter does not seem to influence growth or appearance of bacteria (fig 
2.15). 
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Transformation of pGLysivb into the E.coli K12 strain NM522 (pSIP-H5) 
E.coli K12 strain NM522 (pSIP-H5) subsequently was transformed with pGLysivb in order to 
generate BGs by E-lysis. Successful transformation was confirmed by plasmid preparation and 
subsequent restriction enzyme analysis (fig 2.19a&b). All different states of the plasmid can be seen, 
the unrecombined motherplasmid, miniplasmid and minicircle, uncut as well as single cut. It can be 
seen that the uncut bands of pGLysivb and the pSIP-H5 minicircle are situated close together at about 
5kb, leading to possible confusion of the bands at lower resolution. 
Growth time of the double transformed strain (pSIP-H5, pGLysivb) is slower than of the strain only 
harboring pSIP-H5, mounting up to 250 minutes of growth time to reach an OD600 of 0,2-0,3 from an 
initial (inoculation-) OD600 of 0,05-0,1 (fig 2.20). In order to provide a constant concentration of 
arabinose in an estimated longer recombination time, a second addition of 0,25% arabinose was 
carried out 30 minutes after the first.  
Plasmid preparation of the fermentation shows a slight miniplasmid band already in the second lane 
(fig 2.22, -60min), which depicts the culture immediately before induction of recombination. This 
band points to slight premature recombination. The lane of -30 minutes (3
rd
 lane) already shows a 
slight minicircle band indicating onset of recombination upon arabinose induction. In the lane of 0 
minutes (4
th
 lane, 60 minutes after first dose of 0,25% arabinose) minicircle is clearly visible, 
miniplasmid band strength increases strongly. 60 minutes after lysis induction by temperature shift, 
the pSIP-H5 motherplasmid band starts diminishing (lanes 7-10), which in this case next to 
recombination of the plasmid, can also be attributed to expulsion of the plasmid with the cytoplasm 
following E-lysis. Strong miniplasmid and minicircle bands however, suggest abundant 
recombination, although there are no data available to confirm completeness of the recombination 
event. 
Already 30 minutes after the first induction of the PBAD promoter by arabinose addition, western blot 
shows a LacI band at 45kDa, signifying LacI-L’anchor fusion protein expression (fig 2.23), correlating 
with former results of protein expression (fig 2.17). Visible bands in the second and third lane (-60 and 
-30 minutes) just below 40kDa show genomic LacI expression of E.coli host strain NM522 (fig 2.23). 
Genomic LacI conversely, does not attach to the membrane since it is not fused to the L’anchor and 
therefore is expulsed with the cytoplasm upon lysis. 
There is no direct indication, that second addition of arabinose has any lasting effect on 
recombination. The overall duration of recombinant protein expression (LacI-L’anchor fusion protein 
and parA resolvase) and recombination itself does not alter significantly from results of single-dose 
addition of arabinose. 
Averaged lysis efficiency over all 4 clones adds up to 99,992% following cfu count (fig 2.20) topping 
results of 99,7% of lysis efficiency for the plasmid found in earlier investigations (Champeimont 
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2007). Microscopic pictures of the culture one hour after addition of arabinose (immediately before 
lysis induction) and three hours after lysis induction (fig 2.21) shows E.coli K12 strain NM522 
bacteria and BGs respectively. 
Lysis and recombination profile as well as confirmed PBAD controlled protein expression led to the 
progression to fermentation of the E.coli K12 NM522 (pSIP-H5, pGLysivb) in the 30l bioreactor; thus 
producing enough BGs loaded with the pSIP-H5 minicircle. 
Fermentation of E.coli K12 strain NM522 (pSIP-H5, pGLysivb) in the 30l 
bioreactor to produce pSIP-H5 minicircle loaded BGs for cell culture or animal 
testing 
In order to determine the clone fermented in the bioreactor, plasmid preparations were done, 
examining the recombination state of the clone (fig 2.24). To produce BGs effectively loaded with the 
pSIP-H5 minicircle, it is a prerequisite to keep the motherplasmid in a non-recombined state until 
fermentation, when recombination is deliberately induced. Any untimely generation of miniplasmid by 
recombination means a growing disadvantage for motherplasmid carrying bacteria, propagating slower 
and continuously reducing the motherplasmid/miniplasmid ratio within the culture.  
Due to the restriction enzyme analysis it was observed, that clone 3 already showed a slight 
miniplasmid band, leaving clone 6 (without miniplasmid band) the favored candidate for large scale 
fermentation. 
The growth time of the culture to reach an OD600 of 0,6 in the bioreactor (which corresponds to a 
culture OD600 of 0,2-0,3 in the 30ml flask) was 3 hours after inoculation, which is about 3 to 4 times 
longer than other growth times of (in relation to plasmids and strains) comparable  fermentations 
(Jechlinger, Azimpour Tabrizi et al. 2004). 
Recombination was induced by addition of 250ml of 20% arabinose resulting in the induction 
concentration of 0,25% arabinose within the fermentation vessel of 20l. After 1 hour of recombination, 
corresponding with former results (this work), E-lysis was induced with a temperature shift from 36°C 
to 42°C and maintained for 90 minutes before killing surviving cells with addition of antibiotics. 
Plasmid Preparation of the fermentation shows visible and increasing minicircle band 30 minutes after 
PBAD promoter induction (starting in lane 4, -30’ indicating 30 minutes before lysis induction) (fig 
2.29). 
Western blot shows recombinant protein expression 1 hour after induction (fig 2.30) in accordance to 
previously established data (Laham 2004; Tabrizi 2005). 
Due to influence of BPL on DNA another killing agent, a mixture of antibiotics was used instead. The 
interaction of BPL with the DNA attached to the BGs is dealt with above in detail. 
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cfu count shows a lysis efficiency of 99,92% (fig 2.27) which is in accordance with formerly raised 
data. Also in conformity with publicized data is the amount of cfu in the culture, rising to 8,1E07/ml 
(Laham 2004). 
BGs were harvested by centrifugation, washed with dH2O or 500mM saline and lyophilized. Plasmid 
preparations of similar amounts of lyophilized BGs show higher amount of DNA if saline washed than 
in those washed with dH2O (fig 2.31). A reason for this counter intuitive result can be found in the 
solubility of BGs in saline, which is by far smaller than in dH2O. A change in the minicircle 
(molecularly bound to the membrane with the LacI-L’anchor)/miniplasmid (arbitrarily bound to the 
BG) ratio could not be observed. 
rt-PCR targeting the lacOs sequence present on the pSIP-H5 minicircle as well as on the 
motherplasmid, naturally, was carried out to quantify the minicircle load of the BGs. The standard 
used was pSIP-H5 motherplasmid (fig 2.32), since no pSIP-H5 minicircle could be found after 
purification steps of plasmid preparations. Taking into account a weight factor between pSIP-H5 
motherplasmid (standard DNA) to the minicircle (DNA to detect in the samples) of 0,4284. 
PCR showed an average DNA load of 2,4E03 minicircles per saline washed BG and 12,0E03 
minicircles per water washed BG respectively (fig 2.39). The difference in the amount of minicircle 
per BG between water washed and saline washed BGs may be found in the chaotropic properties of 
the saline, more eagerly disrupting weak molecular bonds (hydrogen bonds, van der Waals-
interactions or hydrophobic effects), arbitrary (miniplasmid) and defined (minicircle) interactions 
alike. 
Compared to the pSIP-Ova minicircle load per ghost of 575 of the former work of Firas AlLaham the 
amount reached in this work lies about 4 to 20 times higher (Laham 2004). There are no data 
concerning the amount of pSIP-H5 miniplasmid still persisting in the BGs. 
Cell-culture and animal experiments are still to be waited upon to draw precise conclusions concerning 
cellular transfection, bioavailability and immunologic efficacy. 
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Material and Methods 
Bacterial Strains 
E.coli K12 strains 
NM522: sup E thi-1Δ(Lac-proAB)Δ(mcrB-hsdSM) 5(rK-mK-) (F’proABlacIqZΔM15) (MB69) 
(Source: Stratagene, Heidelberg,Germany) 
 
ER2655: FλfhuA2[lon] ompT lacZ::T7geneI gal sulA11 Δ(mcrC-mrr)114::IS10 R (mcr-
73::miniTn10 TetS) 2 R(zgb-210::(TetS) endA1 [d cm] (Source: kindly provided by Wolfgang 
Jechlinger, vet. Uni. Wien) 
 
DH10β: F- mcr AΔ(mrr-hsdRMS-mcrBC)Φ80dlacX74 endA1 recA1 deoR Δ(ara, leu)7697 araD139 
galU galK nupG rpsL λ-; (Source: kindly provided by Wolfgang Jechlinger, vet. Uni. Wien) 
 
TOP10: F-mcrA Δ(mrr-hsdRMS-mcrBC) F80lacZΔM15 ΔlacX74 recA1 deoR araD139 Δ(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG 
 
TB1: F
-
 ara Δ(lac-proAB) [Φ80dlac Δ(lacZ)M15] rpsL(StrR) thi hsdR (Source: kindly provided by 
Wolfgang Jechlinger, vet. Uni. Wien) 
Salmonella Species 
Salmonella enterica subsp. enterica (ex Kauffmann and Edwards) Le Minor and Popoff serovar 
Typhimurium deposited as Salmonella typhimurium (Loeffler) Castellani and Chalmers Designations: 
CDC 6516-60 [4016, CIP 104115, NCTC 12023] Isolation: tissue, animal([172299] pools of heart and 
liver from 4-week-old chickens) Depositor: CDC History: CDC University of Missouri.  
(inserted from the ATCC homepage: ATCC number: 14028; wildtype 
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?ATCCNu
m=14028&Template=bacteria) 
 
SALMONELLA VAC E; ATC vet QI01AE01; vaccine strand for active immunization against 
Salmonella Enteritidis, Phage type 4 (LAH, Cuxhaven, Germany) 
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Plasmids 
Plasmid Length 
[bp] 
Origin Induction Expression Resistance Source 
pGLysivb  6201 Rep 42°C Gene E Gentamycin Lab 
pEPH5  6477 pUC 
19 
T7 promoter Vietnam-H5 Ampicillin, 
Kanamycin 
LAH, 
Cuxhaven 
pSIP-Ova  8314 pUC 
19 
arabinose L’-anchor, 
ParA, 
Ovalbumin 
Ampicillin Lab, Firas 
al Laham 
pSIP-H5  10039 pUC 
19 
arabinose L’-anchor, 
ParA, 
Vietnam-H5 
Ampicillin, 
Kanamycin 
Lab, this 
work 
miniplasmid  5676 pUC 
19 
arabinose L’-anchor, 
ParA, 
Vietnam-H5 
Ampicillin Lab, this 
work 
minicircle  4363 - eukaryotic, 
through CMV-
IE Promoter 
Vietnam-H5 Kanamycin Lab, this 
work 
Microbiologic Techniques 
E.coli and Salmonella o/n cultures 
When taken from the -80°C stock, E.coli as well as the Salmonella strains are incubated in 5ml LBv 
medium; depending on carried plasmid, antibiotics or other supplements are added. The eprouvettes 
containing the medium are kept in a rotor or shaker overnight at 37°C or 28°C respectively; incubating 
Agar plates are also kept 37°C or 28°C respectively using a temperature regulated incubator (Heraeus 
BK5060E) or Controlled Environment Incubator Shaker, New Brunswick Scientific. 
Storage of clones 
All stocks are stored at -80°C in 25% Glycerol. 
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Double Transformation of E.coli NM522 with pSIP-H5 and pGLysivb 
To finally have both plasmids in the E.coli strain, two options were considered. At first, it was tried to 
generate MOPS competent cells out of the strain already transformed with pSIP-H5. This, however, 
did not work and transformants were not obtained. 
In the end it was decided to double transform naked MOPS competent E.coli cells. Transformants 
were picked and incubated o/n in 5ml LBv with Ampicillin, Kanamycin and 5% glucose. From these 
cultures glycerol stocks were made and kept at -80°C. 
Growth, Protein Expression and Lysis of E.coli K12 strain NM522 in small 
scale experiments 
All small scale experiments are carried out in 100ml noseflasks (30ml culture volume). LBv Medium 
is autoclaved within the noseflasks and inoculated with the o/n culture to an OD600 between 0,07 and 
0,1. The noseflasks are incubated in a stirring waterbath at 36°C and constant OD600 measurements are 
carried out with the Spectronic 20 Milton Roy Spectrophotometer, defining the growth period of the 
culture and timing of sample taking. At an OD600 of 0,3 expression of the PBAD promoter is induced by 
adding 375µl of 20% arabinose, adding up to a total arabinose concentration within the flask of 0,25%. 
This expression-OD600 was chosen, because an expression time of about one hour was anticipated, 
leaving the culture enough time to reach an OD600 of between 0,4 and 0,5 when lysis will be induced 
by temperature shift from 36°C to 42°C.  
If the experiment does not include lysis, expression is carried on for 1-2 hours, taking samples due to 
protocol.  
Temperature at 42°C for lysis induction is maintained for 3-4 hours for sampling. The cultures are 
discarded by autoclaving. 
Sample taking for Plasmid Preparation, Western Blot, Microscopic Observation 
To observe culture growth and lysis efficiency the OD600 is measured constantly and noted. 
Furthermore samples are taken at distinct timepoints, which themselves are chosen to match 
requirements established by former observation and are therefore due to change. Following scheme 
gives an idea of the sample-taking timetable (table 1). 
The numbers on the right (1-4) indicate the noseflasks of which corresponding samples (western blot, 
miniprep, cfu or microscope) are taken; in this case from all of them. To take the samples, noseflasks 
are rapidly transferred under the lamina. 1ml is taken for miniprep as well as for western blot samples. 
Both are spinned down 1min at 13krpm and supernatant is discarded for miniprep- or kept separately 
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for western blot samples respectively and kept at -20°C until used (for further information on western 
blot process see Western blot in General SOPs below). For plasmid preparation the PeqLab miniprep 
Kit I or II was used, following manufacturers manual. 100µl of the culture are used to commence 
dilution for cfu count (for dilution scheme and further handling see Determination of live cell count 
via colony forming units in General SOPs below). For microscopic observation another 8µl are taken 
out and put on a microscopic slide immediately. 
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table 1.: Timetable and sample-taking schedule 
 
MRA 
           
 
10/16/2007 
 
NM522 
psipH5, pGlysivB 
NM522 
psipH5, pGlysivB 
NM522 
psipH5, pGlysivB 
NM522 
psipH5, pGlysivB 
     
  
Kolben 1 2 3 4 
     
Time: Min: Nr. 
30 ml LBv + Amp + Gent 
36°C + 0,25%  
arabinose at A,  
42°C at C 
30 ml LBv + Amp + 
Gent 
36°C + 0,25%  
arabinose at A,  
42°C at C 
30 ml LBv + Amp  
+ Gent 36°C + 0,25% 
(375µl) 
arabinose at A  
and again at B 
42°C at C 
30 ml LBv + Amp  
+ Gent 36°C + 0,25% 
(375µl) 
arabinose at A  
and again at B 
42°C at C 
OD CFU WB Miniprep microscope 
    O/N         1-4     1-4   
                        
                        
9:45 -245   0.05 0.06 0.05 0.05           
12:00 -110   0.13 0.14 0.13 0.16           
12:50 -60 A (OD 0,2) 0.20 0.23 0.19 0.19 1-4 1-4 1-4 1-4   
13:20 -30 B 0.28 0.29 0.29 0.28 1-4 1-4 1-4 1-4   
13:50 0 C 0.41 0.43 0.40 0.41 1-4 1-4 1-4 1-4 1-4 
14:10 20 D 0.50 0.51 0.50 0.50 1-4 1-4 1-4 1-4   
14:30 40 E 0.25 0.28 0.33 0.29 1-4 1-4 1-4 1-4 1-4 
14:50 60 F 0.23 0.25 0.24 0.24 1-4 1-4   1-4   
15:20 90 G 0.23 0.23 0.24 0.23 1-4 1-4   1-4   
15:50 120 H 0.23 0.24 0.22 0.23 1-4 1-4 1-4 1-4   
16:50 180 I 0.23 0.24 0.21 0.21 1-4 1-4 1-4 1-4 1-4 
inoculate flasks with OD: 0,07-0,1 
         at A: induction with 0,25% arabinose   
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Fermentation of E.coli K12 strain NM522 
Machine, Sterility and Observance 
For the large scale fermentation a 30L bioreactor is used (Techfors S1820, Infors AG) containing 22L 
of working LBv medium, which is sterilized in situ by autoclaving. To prove sterility the milieu within 
the bioreactor (pO2, pH, temperature, air-flow, impeller frequency) is closely observed by the IRIS-
program starting 18h before inoculation, furthermore immediately before inoculation medium samples 
are taken and checked for sterility by plating.  
Inoculation 
4 times 5ml LBv medium are inoculated with a scratch of the chosen clone of the -80°C glycerol 
stock. When medium is dense, this volume is used to inoculate 4 times 50ml of LBv medium, which 
then are incubated until dense and on their part used to inoculate 4 times 500ml of LBv medium. 
These 500ml are incubated o/n and used to inoculate the fermenter. At all times during growth of the 
inoculation culture the medium is kept with corresponding antibiotics and supplements 
When sterility of the fermenter is shown, it is inoculated by 1-2l (depending on OD600) of the o/n 
culture. 
Process 
Also during fermentation the whole growth process is observed by the IRIS program. 50ml samples 
are taken and handled correspondingly to the small scale experiments. Additionally, at the large scale 
fermentation 15ml samples are taken in pairs for rt-PCR. 
Killing 
To inactivate remaining live bacteria after the lysis process, a double dose of Streptamycin and 
Tetracyclin (4,4g Streptamycin [0,22g/l] and 440mg Tetracyclin respectively [0,022g/l]) were added, 
differing from normal killing method. Reasons for the adaption of the fashion of inactivation can be 
found in Adaption of the killing process after fermentation in results. 
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Harvesting 
The ghosts are harvested by centrifugation using the Westfalia Seperator, type CTC1-06-107. The 
harvest process is closely observed and inflow and outflow are regulated by hand, keeping an outflow 
OD600 of less than 0,1 to efficiently extract all material. 
Washing and Lyophilisation 
The harvested material is washed with dH2O or 500mM saline respectively. In both cases material is 
divided into 3 parts and washed with a total of 7200ml in three washing steps á 2400ml. Between the 
washing steps the tubes are centrifuged at 8krpm for 15min at 4°C in a cooling centrifuge, Hermle 
ZK401. After the last washing step the pellet is resuspended in 200ml (either dH2O or 500mM saline) 
and divided into 11 lyophilisation bottles. After pre-cooled at -20°C, the bottles are kept at -80°C. 
Bottles are lyophilisated for 3 days in a lyophilisator, LYOLAB B, LSL SECFROID. 
Calculation of lysis efficiency and particles/mg ratio 
To obtain lysis efficacy, the highest and the lowest cfu are compared and their quotient results in 
efficacy: 
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To obtain the particles/mg of the lyophilized material again the highest cfu is multiplicated by the 
volume of culture, divided by the lyophilized weight of the harvest. 
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Molecular Techniques 
Cloning of pSIP-H5: Overview 
Procedure: 
1. Transformation of plasmid Prep of pEPH5 redissolved from filter paper sent form LAH,      
Cuxhaven, into E. coli strain; plated on Ampicillin Agar. 
2. Inoculation of Transformants in 5ml LBv +Amp, o/n on 37°C, plasmid preparation of pEPH5. 
3. PCR of template H5, using primers noted above, introducing the restriction sites BstBI and PsiI to 
the fragment. 
3. Control of PCR fragment on 1% Agarose gel (check size: 3049bp)  
4. Inoculation of NM522 (pSIP-Ova): 5ml LBv + Amp [100µg/ml] + 5% glucose 
5. Plasmid preparation of pSIP-Ova 
6. Restriction of pSIP-Ova as well as the H5 PCR fragment using BstBI and PsiI  
7. 1% Agarose separation of fragments (check sizes: 6998bp and 1316bp). Use Gel-extraction-kit to 
extract 6998bp fragment out of gel as well as for purifying PCR fragment. 
8. Ligation of pSIP backbone fragment and PCR H5 fragment. After incubation of 6h at 4°C NM522 
cells were transformed with half of the ligation solution and plated on Ampicillin plates +5% glucose. 
The other half is incubated on 4°C o/n and transformed afterwards.  
9. Incubate Transformants in 5ml LBv + Amp + 5% glucose 
10. Plasmid preparation of culture 
11. Control with restriction-digest of pSIP-H5 
12. Sequence of H5 has to be controlled by sequencing 
13. Construct has to be tested in noseflask 
 
Preparing the plasmid pEPH5 for PCR 
The plasmid pEPH5 was sent to us by LAH, Cuxhaven on filter paper, received on 23
rd
 of April, 2007. 
Three small areas, where plasmid solution has been applied were marked with pen. Under the Lamina 
and with sterilized scissors one of the patches was cut out, put into a 1,5ml Eppendorf tube and soaked 
in 50µl of microbiological water (ddH2O), resuspending the plasmid for 5min. After centrifugation at 
13krpm for 1min 10µl of the solution were used to transform 100µl of competent E.coli NM522. The 
Transformants were plated on Agar plates with Ampicillin and incubated o/n at 37°C. Growing clones 
75 
 
were picked the next day and 5ml LBv tubes with Ampicillin were inoculated and incubated at 37°C 
in the rotor. The plasmid preparation then was used for PCR, following the procedures stated below. 
Amplification of the H5 sequence from pEPH5 by PCR 
PCR:     Template: pEPH5 
    PCR fragment: 3049bp 
 
Primer: 
 FwdSIP-H5: 
5´-GAC TTC GAA ATG GAA AAG ATC GTG CTG3´ Tm= 62°C 
 BstBI 
 RevSIP-H5: 
3´-ATA ACA TTA TAA TGC TAG ATA ACT TCG TAT AA´ Tm= 51°C 
   PsiI 
 
PCR cycle:  initial cycle: 
   95°C  3min 
  30 cycles:  
   95°C  30sec 
   50°C  30sec 
   72°C  100sec 
  1 cycle: 
72°C  10min  
end 
   4°C  ∞ 
 
Recipe: 50µl pcr MasterMix fermentas 
 40µl ddH2O 
 1µl fwd primer 
 1µl rev primer 
 8µl template DNA 
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Purifying the H5-insert 
After checking the molecular weight of the PCR fragment, it was restricted with BstBI and PsiI to 
prepare the endings for ligation. After restriction process DNA was purified applying the purifying 
steps of the Gel-extraction-kit. 
 
Preparing pSIP backbone from plasmid pSIP-Ova 
A -80°C glycerol stock (‘projects’) of Firas Al Laham (Srivastava and Liu 2003) of E.coli K12 strain 
NM522 harboring the pSIP-Ova plasmid was used for inoculating 5ml LBv tubes +Ampicillin and 5% 
glucose, in order to repress the PBAD-Promoter, and incubated at 37°C in the rotor o/n. When the 
cultures were dense, the plasmid pSIP-Ova was prepped and control-cut. E.coli K12 strain NM522 
was transformed with the plasmid, cells plated on Agar plates with Ampicillin and 5% glucose and 
incubated o/n at 37°C. Positive clones were picked and used for inoculating 5ml LBv tubes 
+Ampicillin and 5% glucose. From these cultures -80°C glycerol stocks were made. This strain then 
was used for preparation of the pSIP backbone fragment. The plasmid preparation was cut with BstBI 
and PsiI. Due to different manufactures the performance of the restriction enzymes were tested. BstBI 
was bought from Fermentas™ as a FastDigest®-enzyme whereas or PsiI was bought from NEB™. 
The test showed that actually each combination of buffer and enzyme worked and the plasmid was cut 
correctly and efficiently, no difference in efficiency or accuracy was found (data not shown). 
 
Purifying the pSIP backbone 
Plasmid pSIP-Ova preparation was double digested with BstBI and PsiI in NEB-Buffer B for 2h at 
37°C. The fragments (6998bp, the backbone and 1316bp, the Ova-gene) were separated by 
electrophoresis in a 1% Agarose gel. The backbone-band was cut out under mild UV-illumination and 
the DNA purified using the QIAGEN™ (QIAquick® PCR Purification Kit) following manufactures 
manual. 
 
Ligation of the pSIP backbone with H5-gene 
Both DNA preparations were applied to agarose gel electrophoresis. The amounts of DNA of each 
fragment within the ligation recipe were set up in accordance to the intensity of the bands in the gel. 
After 6h of incubation at 4°C 10µl were taken and used for transformation into NM522 MOPS 
competent cells. They were incubated at 37°C o/n on Ampicillin Agar plates with 5% glucose. The 
rest of the Ligation-solution was further incubated at 4°C o/n and used for NM522 MOPS competent 
cell transformation the next day. The cells again were striked out on Ampicillin Agar plates with 5% 
glucose and incubated at 37°C o/n. Transformants were picked from both incubations and inoculated 
in 5ml LBv tubes with Ampicillin and 5% glucose. The cultures were incubated on 37°C o/n in the 
rotor and glycerol stocks were made. 
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Quantification of the minicircle within the BGs 
To determine the amount of minicircle DNA within the Bacterial Ghosts Realtime-PCR was used. The 
sequence amplified by rt-PCR was the LacOs sequence which is present on the minicircle, but not on 
the miniplasmid. As rt-PCR sample 5mg of whole lyophilized BGs were resuspended in 500µl ddH2O. 
This solution was diluted 1:20, 1:2e02, 1:2e03, 1:2e04 and 1:2e05. It also was made sure, that any 
original genomic sequence, which might still be attached to the membrane shell and be amplified by 
the primers, would not forge the measurements. Primers are kept at -80°C.  
 
recipe: 12,5µl SybrGreen® pcr Mastermix of BioRad® 
 5,5µl ddH2O 
 1,0µl fwd primer (equals 1pmol) 
 1,0µl rev primer (equals 1pmol) 
 5,0µl template (different BG dilutions or Standard dilutions respectively) 
 
primers: fwd:  5´-TGG AAC TCA ATA CGA CGG CG- 3´ 
 
rev:  5´-CGG TCG TGA AGG TGT TGC TC- 3´ 
 
amplifying a sequence of 233 bp 
 
Calculation of minicircle per ghost: 
 
 
 
Mass of the DNA will be obtained by the rt-pcr. 
 
Number of BG will be determined through weight of the sample and particle/mg ratio of sample 
(calculation see Calculation of lysis efficiency and particles/mg ratio above). 
 
Mass of minicircle is calculated by the following: 
 
 
 
The mass of 1kb of dsDNA is 6,6x10
5
Da. One Da equals 1,66x10
-27
kg. 
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In respect to the 4363bp long minicircle, the weight of one molecule is: 4,7801E-12µg 
rt-PCR Standard 
The standard was purified motherplasmid. The length of the two DNA molecules (motherplasmid and 
minicircle) differs by a factor of 0,4284. The DNA concentration of the standard was calculated by 
following equation: 
 
 
The [DNA] will result in [µg/ml] 
The OD280 is optical density at 280nm 
DF is the Dilutionfactor 
MF is the Multiplicationfactor, which depends on the type of nucleic acid measured. In this case this is 
dsDNA, and the dilutionfactor is 50. 
rt-PCR program 
The program for amplification was transferred from the protocol of the same pcr of Firas Al-Laham: 
initial cycle 
95C°  3min 
30 cycles 
 94°C  45sec 
 60°C  90sec 
1 cycle 
 4°C  ∞ 
 
Fluorescent measurements were taken each extension step. A Melting Curve was established at the 
end of amplification cycles by increasing temperature every 5s from 60°-95°C. At the end of the run 
the PCR machine cools down to 4°C in order to maintain good DNA quality, if the samples are not 
taken immediately for further use. 
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General Standard Operating Procedures: 
Agarose-Gel 
Corresponding to DNA-length either a 1% (10
3
-10
4
bp) or 2% (10
2
-10
3
bp) Agarose-Gel was used to 
separate DNA-fragments. Following recipe was used to produce the Agarose-Gel, perform the 
separation, staining DNA to take a photograph of the stained DNA: 
 
1.0 Casting of the Gel: 
1.1 3g of Agarose (6g respectively, for 2% Gels) were mixed with 300ml 1xTAE 
1.2 Mixture was heated with microwave (750W) for several minutes until boiling point, 
shaken several times and heated again, until any solid Agarose dissolved. 
1.3 Liquid Agarose was cooled down to hand warm and then cast into the gel casting tray, 
where several combs were applied. 
1.4 When gel was solidified, it was stored in 1xTAE solution until used 
 
2.0 Loading of the Gel: 
2.1 A part with enough slots was cut from the gel. 
2.2 DNA is applied into the slots after mixing with 6xloading buffer, mostly 2µl loading 
buffer with 10µl DNA solution, but amounts may vary, depending on DNA 
concentration of the solution. 
2.3 For the marker mainly 5µl of the 1kb DNA ladder was used. 
 
3.0 Running of the Gel: 
3.1 A voltage of about 150V was applied for about 30-50min 
3.2 Depending on the length of the gel or the DNA fragment, the applied times of running 
of the gel varies and the end of the run is determined by the stained lanes of the 
loading buffer, whenever they reach the end of the gel. 
 
4.0 Staining of the Gel: 
4.1 After the run the gel is transferred to a staining bath, which contains GelRed® 
(BIOTREND). 
4.2 After 10 to 15min, depending on DNA-concentration, length and dye-concentration 
the gel was stained sufficiently to be photographed, illuminated at 250nm. 
 
80 
 
Antibiotics 
All antibiotics used, were bought from (Carl Roth, Germany) in solid state, and dilution and end 
concentration respectively were made in the lab. 
Name [stock solution] [final solution] making of 
Ampicillin 50mg/ml 100µg/ml 2g Ampicillin + 40ml dH2O 
Gentamycin 10mg/ml 20µg/ml 0,4g Gentamycin + 40ml dH2O 
Kanamycin 25mg/ml 50µg/ml 1g Kanamycin + 40ml dH2O 
 
All antibiotics were stored at 4°C. Ampicillin was not longer than 7 days at 4°C, otherwise stored at  
-20°C. Long-term storage of all antibiotics at -20°C. 
Production of CaCl2/RbCl2 competent cells 
1. Growing of the cells 
1.1 Noseflask with 30ml medium is inoculated with the bacteria. 
1.2 Culture is grown in waterbath at 36°C under sterile conditions to an OD600 of 0,5. 
2. Treatment with MOPS solutions 
2.1 Centrifuge culture at 4°C at 4krpm for 10min. 
2.2 Decant supernatant 
2.3 Resuspend pellet in 6ml cold MOPS I and keep on ice for 10min. 
2.4 Centrifuge culture at 4°C at 4krpm for 10min. 
2.5 Decant supernatant 
2.6 Resuspend pellet in 6ml cold MOPS II and keep on ice for 30min. 
2.7 Centrifuge culture at 4°C at 4krpm for 10min. 
2.8 Decant supernatant 
2.9 Resuspend Pellet in 480µl MOPS II and 180µl glycerol. 
2.10 Keep on ice for 10min 
2.11 Aliquot in 100µl and store at -70°C 
Determination of live cell count via colony forming units 
For several important timepoints during the fermentation, like inoculation, expression induction and 
lysis induction and termination the culture concentration is very important. The cell count is 
determined crudely by OD600 measurement and precisely by cfu total. For the plating of the bacterial 
samples a spiral plater (WASP-system, Don Whitley Scientific Ltd, West Yorkshire, GB) was used and 
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colonies counted by a colony counter (Synbiosis ProtoCOL Colony Counter 3.15, Synoptics Ltd., 
Cambridge, UK). 
 
1.0 Dilution of the culture sample: 
1.1 OD600 is measured and determines the dilution of the sample for plating. The accordance 
is given by following table: 
 
 before lysis/growth after lysis-induction 
OD600 (pure) Dilution  OD600 (pure) Dilution 
0,05-0,5 10
4
  1,5-1,0 10
5
 
0,5-1,0 10
5 
 1,0-0,5 10
4 
1,0-2,0 10
6
  0,5-0,2 10
3 
   0,2-0,01 10
2 
 
1.2 The culture is diluted with 0,85% saline, using eprouvettes containing 9ml saline for 
1:10
1
 dilution. 
1.2.1 9ml saline + 1ml culture 
 eprouvettes containing 9,9ml saline are used for 1:10
2
 dilutions. 
1.2.2 9,9ml saline + 100µl culture 
1.3 50µl and 100µl of the end-dilution are plated with the spiral plater. 
1.4 Plates are incubated at 36°C or 28°C depending on the period of incubation until colonies 
are large enough to be read by the colony counter. 
Only plates between 20 and 500 colonies are counted. 
MOPS-Transformation 
All transformations of E.coli were CaCl2/RbCl2 transformations, carried out following the subsequent 
protocol.  
1. 2-10µl of DNA (depending on plasmid preparation) are pipetted to 100µl of competent cells 
(see SOP on preparation of CaCl2/RbCl2-competent cells) 
2. Mixture is kept on ice for 30’ 
3. Heat shock at 36°C or 42°C (depending on the plasmid) for 2’  
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4. Mixture is kept on ice for 5’ 
5. 700µl of LBv-medium +5% glucose is added and cells are incubated for 1h at 37°C 
6. Solution is stroke on 2 agar plates with the corresponding antibiotic, 5% glucose, 100µl and 
the rest. 
7. Plates are incubated mostly overnight at 36°C 
Preparing of electrocompetent cells 
1. Growing of the culture 
1.1 Noseflask with 30ml medium is inoculated with the bacteria 
1.2 Bacteria is grown in waterbath at 36°C under sterile conditions to an OD600 of 0,4 
 
2. Treatment of the culture 
2.1 Keep on ice for 30min 
2.2 Centrifuge at 4°C and 4krpm for 10min 
2.3 Decant supernatant 
2.4  Resuspend pellet in 30ml 10% glycerol 
2.5  Centrifuge at 4°C and 4krpm for 10min 
2.6  Decant supernatant 
2.7  Resuspend pellet in 15ml 10% glycerol 
2.8  Centrifuge at 4°C and 4krpm for 10min 
2.9  Decant supernatant 
2.10 Resuspend pellet in 600µl 10% glycerol 
2.11 Centrifuge at 4°C and 4krpm for 5min 
2.12 Decant supernatant 
2.13 Resuspend pellet in 300µl 10% glycerol 
2.14 Aliquot 50µl 
2.15 Store at -70°C 
Recipes 
Low Salt LBv-Medium (Lennox) 
All growth of bacteria took place in Lennox medium or agar, which was either freshly prepared or 
stored at 4°C for not longer than two weeks after autoclaving. 
The recipe for 1l: 
1. 10g Peptone 
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5g Yeast extract 
5g NaCl 
2. The ingredients were dissolved in 900ml dH2O 
3. The pH was adjusted to 7,4 with NaOH (1N) 
4. If Agar was made, 15g of Agar were added at this point 
5. After completing to 1l with dH2O the medium (agar or no) was autoclaved 
Any supplements like antibiotics or glucose are to be added after autoclaving and after the solution 
had cooled down to hand warm temperature. 
In case of Agar, when hand warm temperature was reached, it was poured into petri dishes (ca. 20ml) 
next to the gas flame and left covered, until solidified and used immediately or stored at 4°C not 
longer than 2 weeks. 
 
MOPS I  
 10.47g MOPS I (100mM) 
 0.47g CaCl2 x 2H2O (10mM) 
 0.6g RbCl2 (10mM) 
Dissolve ingredients in 400ml dH2O and adjust to pH=7 using KOH. Fill up to 500ml and sterilize by 
autoclaving. 
 
MOPS II 
10.47g MOPS I (100mM) 
5.15g CaCl2 x 2H2O (10mM) 
 0.6g RbCl2 (10mM) 
Dissolve ingredients in 400ml dH2O and adjust to pH=6,5 using KOH. Fill up to 500ml and sterilize 
by autoclaving. 
Digest with Fermentas® FastDigest® Enzymes 
All restriction enzyme cuts were done with Fermentas® FastDigest® Enzymes except otherwise 
stated.  
1. Enzymes are stored at -20°C, when working enzymes are kept in the freeze-block 
1.1 Recipe: 
3µl of DNA (plasmid preparation) 
1µl of FastDigest® restriction enzyme 
1µl of FastDigest® Buffer 
5µl of ddH2O 
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1.2 Ingredients are mixed together in an Eppendorf under the lamina 
1.3 Eppendorf is incubated at 37°C for about 20min 
Ligation 
For the Ligation the T4 ligase, NEB, was used and the whole process was performed due to 
manufacturers’ instructions. Insert to vector relation was approximately 1:10. The plasmid pSIP-H5 
was ligated in two ways, differing in the ligation time. After mixing of the ligation ingredients, it was 
incubated at 4°C for about 6h, when the first aliquot was taken and used for transformation, the rest of 
the solution was kept at 4°C overnight and again an aliquot was taken and a second transformation 
was carried out. 
Western Blot 
The presence of the LacI-L‘anchor was determined by westernblotting. The LacI-L’anchor gene lies 
upstream of the recombinase gene and both are under control of the same promoter PBAD.  
At different time points samples of the growing and lysing culture were taken. Usually 1ml of culture 
was centrifuged and the supernatant was separated from the pellet and kept, at -20°C 
1.0 Taking of the sample: 
1.1 1ml of the culture is taken into an eppendorf tube and centrifuged at 10000rpm for 1-
2min. It is important to know the OD600 of the culture at the corresponding timepoint. 
1.2 The supernatant is transferred to an extra tube. 
1.3 If the sample is not directly prepared for western blot it is kept at -20°C 
 
2.0 Preparing the sample for western blot: 
2.1 The measured OD600 is multiplied by 250, which then gives the amount of NuPage 
Reducing Sample-Buffer, Invitrogen, added to the pellet. 
2.2 The pellet is thoroughly resuspended in the buffer. 
2.3 The tube then is heated to 99°C for ten minutes, to denature all protein. 
 
3.0 Applying the sample on the gel (4-12% gradient BisTris-Gel Novex, Invitrogen): 
3.1 The precast gel is stored at 4°C and placed into the tank chamber just before 
electrophoresis. MES-running buffer, Invitrogen, is added, sufficient to cover both 
sides (up and down) of the gel. 
3.2 The sample is centrifuged shortly at high-speed to sediment any solids. 
3.3 15µl of the supernatant are applied per slot. 
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3.4 5µl of marker (PageRuler™ Unstained Molecular Weight Marker, Fermentas) are 
applied at each end of the sample-set. 
3.5 The electrophoresis takes place at 120V (for two gels in one tray) for about 40min. 
The sample buffer shows blue bands which indicate the running-front. 
 
4.0 Blotting the sample 
4.1 The gel is placed upon a nitrocellulose membrane, which is already wetted in transfer 
buffer, the edges of the gel marked with a pen. 
4.2 A special order of sponge-pads and filter paper (all saturated with NuPage Transfer 
buffer, Invitrogen) are applied to either side of the gel. This whole stack is then placed 
into the blotting apparatus. 
4.3 The blotting takes place at 60V (for two gels) and for about 1h. 
4.4 For cooling reasons water was added to the outside of the blotting apparatus. 
 
5.0 Staining and Blocking of the membrane: 
5.1 The gel and filter paper are discarded and the membrane stained with Ponceau S stain. 
5.2 After the marker bands are penciled over, the membrane is washed again with water in 
order to remove the Ponceau S staining again. 
5.3 Blocking Solution (1x Roti-Block™, Roth) is added to cover all of the membrane. 
5.4 The membrane is stored in the Blocking Solution at 4°C overnight. 
 
6.0 Antibody incubation: 
6.1 After the blocking the membrane is washed 3 times for about 5-10 minutes in TBST 
on the shaker 
6.2 About 20ml of the primary antibody, a rabbit derived anti-LacI antibody (1:5000) is 
used and incubated for 1h on the shaker. 
6.3 The antibody is taken off the membrane and stored for further use. The membrane is 
washed three times for about 5-10minutes each washing step in TBST. 
6.4 The membrane is incubated for 1h in the secondary antibody, a goat anti-rabbit 
antibody associated with HRP (1:5000). 
6.5 The membrane is washed three times, 5-10min each step, in TBS. 
 
7.0 Staining and imaging of the membrane: 
7.1 The membrane is soaked in 6ml of premixed Chemiluminescent Substrate SantaCruz 
Biotechnology for several minutes 
7.2 The membrane is documented in the Chemidoc device 
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